33rd

European Society of Hypertension

Hochdruckliga

EUROPEAN MEETING ON HYPERTENSION AND CARDIOVASCULAR PROTECTION

BERLIN

MAY 31 - JUNE 3, 2024

www.eshannualmeetings.eu

SCIENTIFIC PROGRAMME

ANNUAL MEETING COMMITTEES

LOCAL ORGANIZING COMMITTEE

R. Kreutz
R.E. Schmieder
M. van der Giet
K. Kusche-Vihrog
F. Limbourg
U. Wenzel
E. Wühl

SCIENTIFIC PROGRAMME COMMITTEE

E. Agabiti Rosei
E. Algharably
S. Alshuraf
P.A. Modestini
M. Azizi
A. Benetos
A.E. Berbari
J. Brguljan
R.M. Bruno
M. Brunström
M. Burnier
A.J. Danser
T. De Backer
R. de Pinho
C. Delles
K. Dimitriadis
D.R. Dimulescu
M. Doumas
B. Duly-Bouhanick
S. Erdine
A. Erhartiĉ
M.S. Fernandez Alfonso
T. Frese
J.A. Garcia-Donaire
R. Gómez Huelgas
G. Grassi
J. Gulnara
J.-M. Halimi
L.V. Halvorsen
D. Hering
M. Ibrahim
A. Januszewicz
Z. Jarai
B. Jelakovic
K. Kario
V. Kotsis
A. Leibowitz
G. Mancia
H.P. Marti
T. McCormack
M. Miglinas
M.L. Muiesan
P. Mulatero
T. Niiranen
P. Palatini
G. Parati
A. Pathak
P. Pauklin
P.S. Perl
A. Persu
J. Polonia
A. Postadzhiyan
E. Rodilla Sala
M. Schlaich
A.E. Schutte
Y. Sirenko
Š. Sokoloviĉ
J. Spaak
S. Stabouli
V. Stojanov
P. Stylianou
C. Thomopoulos
V. Tsinamdzgvrishvili
Bejan
K. Tsioufis
A. Vachulova
B.-J. Van Den Born
R. Veelken
A. Virdis
L. Vogt
J.-G. Wang
C. Wanner
T. Weber
J. Widimský
J. Wolf
G. Wuerzner
E. Yang
P. Zelveian

GENERAL INFORMATION

REGISTRATION OPENING HOURS

Friday, May 31	12.00 - 19.00
Saturday, June 1	7.00 - 19.30
Sunday, June 2	7.00 - 19.30
Monday, June 3	7.30 - 15.00

EXHIBITION OPENING HOURS

Friday, May 31	12.00 - 17.00
Saturday, June 1	9.00 - 17.00
Sunday, June 2	9.00 - 17.00
Monday, June 3	9.00 - 15.00

ADMISSION

Badge is required for all congress activities, including scientific sessions and circulation between the spaces. Lost badges can be replaced for a fee with proof of registration. No children allowed in congress areas.

LANGUAGE

The official language of the Meeting is English. Simultaneous translation will not be provided.

CME ACCREDITATION

The 33rd European Meeting on Hypertension and Cardiovascular Protection provides the opportunity for German medical professionals to earn Continuing Medical Education (CME) credits.
The event has been accredited by the Medical Association of Berlin (Ärztekammer Berlin) for **24 CME points**.

LUNCHES

Box lunches are served upon presentation of the related daily coupon included in your badge.

E-POSTER

A Digital Poster Area will be set up in the Exhibition area.
Poster sessions are scheduled as follows:

Saturday, June 1	18.30 to20.00
Sunday, June 2	11.30 to 13.00
Monday, June 3	13.30 to 15.00

SLIDE CENTER – ROOM 4

Friday, May 31	11.30 - 19.30
Saturday June 1	7.00 - 19.00
Sunday June 2	7.00 - 19.00
Monday June 3	7.30 - 12.30

MEDICAL ASSISTANCE

Participants in need of medical assistance should contact the medical Point located at level 0 of the congress venue.

BE CONNECTED!

Public WI-FI will be available. No password needed.

Facebook: ESH Annual Meetings
Twitter: @ESH_Annual

ORGANISING AND SCIENTIFIC SECRETARIAT

AIM GROUP ITALY

AIM ITALY – Rome office
Via Flaminia, 1068
00189 Rome, Italy
ph +39-06 330531

Servier Medical Hub

Your global partner for medical updates
In cardiometabolic and venous diseases

HYPERTENSION | ANGINA | DYSLIPIDEMIA | HEART FAILURE | DIABETES | MULTIMORBIDITY | VENOUS DISEASE

Scan the QR-code and join the community!

Looking to stay informed on the most recent medical updates in cardiometabolic and venous diseases?
Servier presents a cutting-edge platform tailored to your needs:

www.serviermedicalhub.com

Access a wealth of updated medical content in these domains, featuring recordings from international congress symposia, global webinars, expert interviews, and educational programs.

Access for HCPs only - registration is free: scan the QR code now and create your personal account in 2 simple steps only!

SERVIER moved by you

33rd

EUROPEAN MEETING

ON HYPERTENSION
AND CARDIOVASCULAR
PROTECTION

SCIENTIFIC PROGRAMME

FRIDAY, MAY 31

13.00-14.00 **CONVENTION HALL I C**

Working Group on Endocrine Hypertension

Chairpersons: L. Amar (Paris, FRANCE), A. Prejbisz (Warsaw, POLAND)

13.00-13.11 **Are metanephrines preferable to cortisol for the normalisation of aldosterone values during adrenal vein sampling in primary aldosteronism?**
S. Monticone (Torino, ITALY)

13.11-13.22 **The new guidelines on the management of patients with incidentalomas**
G. Di Dalmazi (Bologna, ITALY)

13.22-13.33 **Risk factors for intraoperative hypertensive crisis in patients with pheochromocytomas and sympathetic paragangliomas**
M. Araujo-Castro (Madrid SPAIN)

13.33-13.44 **Target organ damage in primary aldosteronism - reversible?**
A. Yen-Hung Lin (Taipei, TAIWAN)

13.44-14.00 **Discussion**

13.00-14.00 **CONVENTION HALL I D**

Working Group on Hypertension in Women

Chairpersons: R. Cífková (Prague, CZECH REPUBLIC), C. Thomopoulos (Athens, GREECE)

13.00-13.15 **Changes in blood pressure and cardiovascular risk after menopause**
E. Gkaliagkousi (Thessaloniki, GREECE)

13.15-13.30 **Contraceptive pills and hypertension: current status**
J. Brguljan (Ljubljana, SLOVENIA)

13.30-13.45 **Blood pressure measurements during pregnancy**
M.-L. Lopez-Sublet (Paris, FRANCE)

13.45-14.00 **Discussion**

13.00-14.00 **HALL EUROPE**

Working Group on Environment in Hypertension

HYPERTENSION AND CV COMPLICATIONS DUE TO ENVIRONMENTAL FACTORS – ARE THEY REVERSIBLE?

Chairpersons: R. Kreutz (Berlin, GERMANY), M. Rajzer (Krakow, POLAND), P. van de Borne (Brussels, BELGIUM)

13.00-13.15 **Climate change**
J.-G. Wang (Shangai, CHINA)

13.15-13.30 **Noise pollution**
M. Rajzer (Krakow, POLAND)

13.30-13.45 **Air pollution**
W. Wojciechowska (Krakow, POLAND)

13.45-14.00 **Light pollution**
A. Daiber (Mainz, GERMANY)

13.00-14.00 **ROOM II**

Working Group on Hypertension in Children and Adolescents

ESH GUIDELINES IN CLINICAL PRACTICE: DIAGNOSIS AND MANAGEMENT OF HYPERTENSION IN CHILDREN AND ADOLESCENTS

Chairpersons: T. Seeman (Prague, CZECH REPUBLIC), S. Stabouli (Thessaloniki, GREECE)

13.00-13.10 **Screening for hypertension in adolescents**
D. Drozdz (Krakow, POLAND)

13.10-13.15 **Discussion**

13.15-13.25 **Out of office BP measurements: when and how**
G. Hamdani (Petach Tikvah, ISRAEL)

13.25-13.30 **Discussion**

13.30-13.40 **Diagnostic evaluation of hypertensive adolescent**
T. Seeman (Prague, CZECH REPUBLIC)

13.40-13.45 **Discussion**

13.45-13.55 **Pharmacological treatment for adolescent hypertension**
E. Wühl (Heidelbeg, GERMANY)

13.55-14.00 **Discussion**

13.00-14.00 **ROOM III**

Working Group on Hypertension in low resource setting

ETHNICITY AND CV RISK IN PRIMARY CARE

Chairpersons: P.A. Modesti (Florence, ITALY),
Š. Sokolovič (Sarajevo, BOSNIA AND HERZEGOVINA)

13.00-13.20 **Ethnic differences in blood pressure levels**
B.-J. H. Van Den Born (Amsterdam, THE NETHERLANDS)

13.20-13.40 **Ethnic differences in hypertension management in primary care**
A. Pellegrino (Florence, ITALY)

13.40-14.00 **Left ventricular hypertrophy and mortality in ethnic minority groups**
E. Shantsila (Liverpool, UNITED KINGDOM)

13.30 - 17.30 **ROOM V**

Hands-On Workshop

RENAL ULTRASOUND IN HYPERTENSION (BASICS)

Chairpersons: A. Januszewicz (Warsaw, POLAND),
A. Persu (Brussels, BELGIUM)

13.30-13.35 **Brief history and aims of the course**
A. Persu (Brussels, BELGIUM), A. Januszewicz (Warsaw, POLAND)

13.35-14.05 **Technical basics of ultrasound; normal anatomic findings and common abnormalities of the renal and urogenital tract (renal masses, nephrolithiasis, hydronephrosis)**
M. Januszewicz (Warsaw, POLAND)

14.05-14.35 **Renal duplex ultrasound: atherosclerotic renal artery stenosis and fibromuscular dysplasia / renal resistive index**
B. Ponte (Geneva, SWITZERLAND)

14.35-14.50 **Towards ultrasound-specific criteria for fibromuscular dysplasia: insights from the DYSART study**
F. Silhol (Marseille, FRANCE)

14.50-15.05 **Contrast-enhanced ultrasound: current and future applications in patients with hypertension and/or chronic kidney diseases**
M. Pruijm (Lausanne, SWITZERLAND)

15.05-15.15 **Break**

15.15-17.30 **Practical kidney examination by experts and supervised hands-on kidney ultrasound with healthy volunteers**
D. Ackermann (Bern, SWITZERLAND), U. Eisenberger (Essen, GERMANY), M. Januszewicz (Warsaw, POLAND), B. Ponte (Geneva, SWITZERLAND), M. Pruijm (Lausanne, SWITZERLAND), F. Silhol (Marseille, FRANCE)

14.30-15.30 **CONVENTION HALL I C**

Working Group on Device-Based therapy

ROLE OF RDN IN CARDIOVASCULAR AND HYPERTENSION MANAGEMENT 2023

Chairpersons: K. Dimitriadis (Athens, GREECE), J. Weil (Lubeck, GERMANY)

14.30-14.42 **Patient selection for Renal denervation according to guidelines, consensus statements and labeling**
K. Tsioufis (Athens, GREECE)

14.42-14.54 **Clinical research on renal denervation – where do we stand in 2024**
F. Mahfoud (Hamburg, GERMANY)

14.54-15.06 **Renal denervation beyond hypertension – rational for possible new indications**
R.E. Schmieder (Erlangen, GERMANY)

15.06-15.18 **How to set-up a renal denervation program – a step-by-step guide**
S. Ewen (Villigen, GERMANY)

15.18-15.30 **Renal denervation: Long-term efficacy and safety – what do we know by now**
F. Tatakis (Athens, GREECE)

14.30-15.30 **CONVENTION HALL I D**

Working Group on Pharmacotherapy, lifestyle interventions and adherence

Chairpersons: M. Azizi (Paris, FRANCE),
J. Versmissen (Rotterdam, THE NETHERLANDS)

14.30-14.42 **Chemical adherence testing for personalized feedback in patients with resistant hypertension**
J. Versmissen (Rotterdam, THE NETHERLANDS)

14.42–14.54 **Lifestyle management of hypertension: International Society of Hypertension position paper**
V. Cornelissen (Leuven, BELGIUM)

14.54-15.06 **How to increase partnership between patients and healthcare providers for improving medication adherence**
M. Burnier (Lausanne, SWITZERLAND)

15.06-15.18 **A siRNA targeting angiotensinogen to treat hypertension**
M. Azizi (Paris, FRANCE)

15.18-15.30 **Baxdrostat and other aldosterone synthase inhibitors**
R. Olde Engberink (Amsterdam, THE NETHERLANDS)

14.30-15.30 **HALL EUROPE**

Working Group on Diabetes and Metabolic Risk Factors

Chairpersons: V. Kotsis (Thessaloniki, GREECE), J. Redon (Valencia, SPAIN)

14.30-14.40 **Consensus of EASO and the WG: obesity induced hypertension, diabetes and dyslipidemia in obesity new practice guidelines**
V. Kotsis (Thessaloniki, GREECE)

14.40-14.50 **Lessons of measuring BP in the space environment**
J. Jordan (Cologne, GERMANY)

14.50-15.00 **Obesity and CKD**
B. Jelakovic (Zagreb, CROATIA)

15.00-15.10 **Recent diabetes CVD trials on SGLT2 and GLP1 and their effects on weight and Hypertension?**
P. Nilsson (Lund, SWEDEN)

15.10-15.20 **Hypertension centers of excellence: An opportunity to treat metabolic risk factors beyond blood pressure to reduce total CV risk**
J. Redon (Valencia, SPAIN)

15.20-15.30 **Small and big arteries in the obese patients**
C. Antza (Thessaloniki, GREECE)

14.30-15.30 **ROOM II**

Working Group on Small Arteries

MECHANISMS OF MICROVASCULAR DAMAGE IN CARDIOMETABOLIC DISEASES

Chairpersons: E. Gkaliagkousi (Thessaloniki, GREECE), A. Virdis (Pisa, ITALY)

14.30-14.38 **Erectile dysfunction as a small artery disease condition**
D. Terentes-Printzios (Athens, GREECE)

14.38-14.40 **Discussion**

14.40-14.48 **Endothelial ADAR2 controls immune cell trafficking in ischemic microcirculation by regulating IL-6 signaling**
A. Gatsiou (Heidelberg, GERMANY)

14.48-14.50 **Discussion**

14.50-14.58 **Microcirculation and inflammatory diseases**
G. Pavlidis (Athens, GREECE)

14.58-15.00 **Discussion**

15.00-15.08 **The role of Neutrophil Netosis in target organ damage in Essential Hypertension**
A. Lazaridis (Thessaloniki, GREECE)

15.08-15.10 **Discussion**

15.10-15.18 **Perivascular adipose tissue meta-inflammation in microvascular cardiometabolic diseases**
A. Mengozzi (Pisa, ITALY)

15.18-15.20 **Discussion**

15.20-15.28 **TRPM7 and microvascular inflammation and fibrosis**
F. Rios (Glasgow, UNITED KINGDOM)

15.28-15.30 **Discussion**

14.30-15.30 **ROOM III**

Working Group on Hypertension and the Brain

HYPERTENSION AND COGNITION - HOW TO PREVENT AND DETECT?

Chairpersons: P. Cunha (Guimarães, PORTUGAL),
D. Hering (Gdansk, POLAND)

14.30-14.45 **Cardiometabolic Disease and Brain Damage**
A. Malliora (Thessaloniki, GREECE)

14.45-15.00 **Detection and prevention of cognitive impairment in hypertension**
P. Cunha (Guimarães, PORTUGAL)

15.00-15.15 **Imaging techniques for detection and diagnosis of brain damage**
D. Gasecki (Gdansk, POLAND)

15.15-15.30 **Discussion**

15.30-16.15 **HALL EUROPE**

General Assembly of Working Groups

16.30-17.30 **CONVENTION HALL I C**

Working Group on Blood Pressure Monitoring and Cardiovascular Variability

PRACTICAL "HANDS-ON" COURSE ON BP MEASUREMENT AND MONITORING IN HYPERTENSION

Chairpersons: A. de la Sierra (Barcelona, SPAIN), P. Palatini (Padua, ITALY)

16.30-16.40 **Well standardized attended office BP measurement. Any need for unattended measurement?**
A. Kollias (Athens, GREECE)

16.40-16.50 **Home BP monitoring: correct use and abuse**
G. Parati (Milan, ITALY)

16.50-17.05 **Interpretation of 24-hour BP monitoring**
F. Saladini (Padua, ITALY), G.Bilo (Milan, ITALY)

17.05-17.15 **Any space for Cuffless BPM Devices?**
G.S. Stergiou (Athens, GREECE)

17.15-17.30 **Discussion**

16.30-17.30 **CONVENTION HALL I D**

Working Group on Hypertension and the Kidney

Chairpersons: J.-M. Halimi (Paris, FRANCE),
L. Vogt (Amsterdam, THE NETHERLANDS)

16.30-16.45 **Management of CKD hypertensive patients across Europe**
J.-M. Halimi (Paris, FRANCE)

16.45-17.00 **Dietary intakes in CKD patients: what is the next step**
L. Vogt (Amsterdam, THE NETHERLANDS)

17.00-17.15 **Early Mortality, Cardiovascular, and Renal Diseases in Women's Lives Following Hypertensive Disorders of Pregnancy**
V. Olié (Paris, FRANCE)

17.15-17.30 **Perspectives regarding new ways to blockade aldosterone for cardio and renal benefits**
L. Amar (Paris, FRANCE)

16.30-17.30 **HALL EUROPE**

Working Group on Large Arteries

Chairpersons: E. Bianchini (Rome, ITALY),
D. Terentes-Printzios (Athens, GREECE)

16.30-16.50 **Guidelines for technical validation for PWV devices**
B. Spronck (Maastricht, THE NETHERLANDS)

16.50-17.10 **PWV in clinical practice**
T. Weber (Wels, AUSTRIA)

17.10-17.30 **New projects**
R. M. Bruno (Paris, FRANCE)

16.30-17.30 **ROOM II**

Working Group on Hypertension and the Heart

THE HYPERTENSIVE HEART IN CLINICAL PRACTICE: KEY POINTS OF DIFFERENTIAL DIAGNOSIS

Chairpersons: M. Camafort (Barcellona, SPAIN), S. Masi (Pisa, ITALY)

16.30-16.38 **Imaging of the hypertensive heart: standard methods and advanced options**
E. Agabiti Rosei (Brescia, ITALY)

16.38-16.46 **Differential diagnosis from infiltrative diseases**
M. Spiewak (Warsaw, POLAND)

16.46-16.54 **Differential diagnosis from hypertrophic cardiomyopathy**
A. Kasiakogias (Athens, GREECE)

16.54-17.02 **Athlete's heart or hypertensive heart disease**
D. Antonakaki (London, UNITED KINGDOM)

17.02-17.30 **Discussion**

16.30-17.30 **ROOM III**

Working Group on Hypertension in older adults

MANAGEMENT OF HYPERTENSION IN PATIENTS 80 YEARS AND OLDER

Chairpersons: A. Benetos (Nancy, FRANCE), T. De Backer (Gent, BELGIUM)

16.30-16.45 **Impact of neurocognitive disorders in the diagnostic and therapeutic strategies**
M. Camafort (Barcelona, SPAIN)

16.45-17.00 **Non-pharmacological treatments**
H. Ribeiro (Santa Maria Da Feira, PORTUGAL)

17.00-17.15 **How to start and up-titrate pharmacological treatment?**
A. Virdis (Pisa, ITALY)

17.15-17.30 **Situations in which treatment could be decreased**
J. Sheppard (Oxford, UNITED KINGDOM)

18.00-19.00 **CONVENTION HALL II**

Opening of the Congress

Chairpersons: G. Grassi (Milan, ITALY), R. Kreutz (Berlin, GERMANY), R.E. Schmieder (Erlangen, GERMANY), T. Weber (Wels, AUSTRIA)

18.00–18.05 **Welcome to ESH 2024**
R. Kreutz (Berlin, GERMANY),
R.E. Schmieder (Erlangen, GERMANY)

18.05–18.15 **Present and future of ESH**
G. Grassi (Milan, ITALY)

18.15–18.30 **Future of Health: Challenges in Academic Medicine**
H. Kroemer (Berlin, GERMANY)

18.30–18.45 **My heart is inditing - cardiovascular regulation and disease in the realm of music**
M. Paul (Bochum, GERMANY)

18.45–19.00 **Music Barenboim-Said Akademie**

33rd EUROPEAN MEETING ON HYPERTENSION AND CARDIOVASCULAR PROTECTION

SCIENTIFIC PROGRAMME

SATURDAY, JUNE 1

07.15-08.15 ROOM II

Morning Session

WORKING GROUP BLOOD PRESSURE MEASUREMENT: TAKING BLOOD PRESSURE MEASUREMENT INTO THE 21ST CENTURY - A WAY FORWARD

Chairpersons: A. de la Sierra (Terrassa, SPAIN), P. Palatini (Vittorio Veneto, ITALY), A.E. Schutte (Sidney, AUSTRALIA)

07.15-07.23 **Conventional blood pressure measurement: strengths and weaknesses**
A. Kollias (Athens, GREECE)

07.23-07.31 **New methods on the horizon: Time to revolutionize blood pressure measurement?**
T.L. Bothe (Berlin, GERMANY)

07.31-07.39 **Should we consider average BP levels only or also focus on BP variations?**
G. Parati (Milan, ITALY)

07.39-07.47 **How should we interpret and manage the changes of the diurnal BP rhythm?**
F. Saladini (Cittadella, ITALY)

07.47-07.55 **Blood pressure measurement in patients with arrhythmias**
G.S. Stergiou (Athens, GREECE)

07.55-08.15 **Q&A**

07.15-08.15 ROOM III

Morning Session

SUGGESTED NOVEL RISK FACTORS IN HYPERTENSION: ENVIRONMENTAL FACTORS

Chairpersons: A. Persu (Brussels, BELGIUM), M. Rajzer (Krakow, POLAND)

07.15-07.30 **Night light pollution: The dark side of brightness**
A. Daiber (Konstanz, GERMANY)

07.30-07.45 **Air pollution: Cardiovascular matter of particulate matters**
W. Wojciechowska (Krakow, POLAND)

07.45-08.00 **Noise pollution: It is too quiet about it**
M. Rajzer (Krakow, POLAND)

08.00-08.15 **Climate change: Health aspects of the global problem**
J.-G. Wang (Shanghai, CHINA)

08.30 – 09.30 **CONVENTION HALL I C**

Oral Session 1

EPIDEMIOLOGY 1

Chairpersons: M. Lopez-Sublet (Bobigny, FRANCE), J. Redon (Valencia, SPAIN)

08.30-08.40 AWARENESS, TREATMENT, AND CONTROL OF HYPERTENSION USING OPPORTUNISTIC SCREENING PROGRAMS: EVIDENCE FROM THE MAY MEASUREMENT MONTH CAMPAIGN, 2017-2019

C. Razo [1], T. Beaney [2], N. R. Poulter [2], D. Prabhakaran [3], A.E. Schutte [4], C. Johnson [1], G. A. Roth [1]
[1] Seattle (USA), [2] London (UNITED KINGDOM), [3] New Delhi (INDIA), [4] Sydney (AUSTRALIA)

08.40-08.50 SEX DIFFERENCES IN A CARDIOVASCULAR DISEASE RISK SCORE AND ITS COMPONENTS AS PREDICTORS FOR MULTIMORBIDITY IN THE UK BIOBANK

K. Harris [1], W. Wang[1], C. Carcel[1], S. Peters [1,2,3], M. Woodward [1,2], J. Chalmers [1]
[1] Sydney (AUSTRALIA), [2] London (UNITED KINGDOM), [3] Utrecht (THE NETHERLANDS)

08.50-09.00 RESIDENCE AT HIGH ALTITUDE IS ASSOCIATED WITH LOWER CONVENTIONAL AND AMBULATORY BLOOD PRESSURE THAN LIVING AT SEA LEVEL IN THE GENERAL POPULATION OF PERU. HIGHCARE-LAPS STUDY

G. Bilo [1], F.C. Villafuerte [2], L. Zanotti [1], D. Soranna [1], S. Nava [1], V. Rusconi [1], M.F. Pengo [1], A. Croce [3], C. Lombardi [1], J. L. Macarlupu [2], D. Bermudez [2], J.M. Sosa [2], C.P. Carcamo [2], A. Zambon [1], G. Parati [1]
[1] Milan (ITALY), [2] Lima (PERU)

09.00-09.10 COMPARING BLOOD PRESSURE CONTROL TARGETS GLOBALLY: AN ANALYSIS OF THE MAY MEASUREMENT MONTH 2022 CAMPAIGN IN 60 COUNTRIES

T. Beaney [1], G. Kerr [1], M. Schlaich [2], A.E. Schutte [3,4], G.S. Stergiou [5], N.R. Poulter [1]
[1] London (UNITED KINGDOM), [2] Perth, [3] Sydney (AUSTRALIA), [4] Potchefstroom (SOUTH AFRICA), [5] Athens (GREECE)

09.10-09.20 U-SHAPED RELATIONSHIP BETWEEN BLOOD PRESSURE AND ALL-CAUSE MORTALITY IN OLDER ADULTS: THE SHIZUOKA STUDY

A. Asahina, T. Usui, Y. Tabara
Shizuoka (JAPAN)

09.20-09.30 INTENSIVE BP CONTROL FOR THE PREVENTION OF CARDIOVASCULAR EVENTS AMONG INDIVIDUALS WITH HYPERTENSION AT LOW CARDIOVASCULAR RISK: A TARGET TRIAL EMULATED USING OBSERVATIONAL DATA

A. Douros [1], T. Jiao [2], R. W. Platt [2], P. Reynier [2], K. B. Filion [2]
[1] Berlin (GERMANY), [2] Montreal (CANADA)

08.30-09.45 **ROOM II**

Oral Session 2

METABOLIC COMORBIDITIES

Chairperson: C. Borghi (Bologna, ITALY), J. Jordan (Cologne, GERMANY)

08.30-08.45 MINI-LECTURE
Repurposing antihypertensive drugs for MAFLD/NAFLD
A. Douros (Berlin, GERMANY)

08.45-08.55 **THE INTERPLAY BETWEEN SYMPATHETIC NERVOUS SYSTEM OVERACTIVITY, BLOOD PRESSURE LEVELS AND NON-ALCOHOLIC FATTY LIVER DISEASE IN HYPERTENSIVE PATIENTS**
N. Kakouri, I. Andrikou, D. Konstantinidhs, E. Siafi, E. Manta , M. Koullias, H. Papageorgiou, K. Grigoriou, I. Leontsinis, P. Iliakis, E. Mantzouranis, P. Tsioufis, D. Tousoulis, C. Thomopoulos, K. Dimitriadhs, C. Tsioufis
Athens (GREECE)

08.55-09.05 **NIGHTTIME BLOOD PRESSURE ASSESSED USING HOME OR AMBULATORY BLOOD PRESSURE MONITORS IN YOUNG ADULTS WITH TYPE 1 DIABETES: RELATIONSHIP WITH PRECLINICAL TARGET-ORGAN DAMAGE**
A. Theodosiadi [1], A. Kollias [1], E. Vakali [1], A. Destounis [1], K. Tsiroukidou [2], E. Karypidou [2], A. Menti [1], A. Vazeou [1], I. Zografou [2], M. Doumas [4], G.S. Stergiou [1]
[1] Athens, [2] Thessaloniki (GREECE)

09.05-09.15 **THE ASSOCIATION OF LONG-TERM TRAJECTORIES OF BMI, ITS VARIABILITY, AND METABOLIC SYNDROME: A 30-YEAR PROSPECTIVE COHORT STUDY**
T. Guo [1], S. Zheng [2], T. Chen [3], C. Chu [1], J. Ren [1], Y. Sun [1], Y. Wang [1], M. He [1], Y. Yan [1], H. Jia [1], Y. Liao [1], Y. Cao [1], M. Du [1], D. Wang [1], Z. Yuan [1], D. Wang [2], J. Mu [1]
[1] Xi'An (CHINA), [2] Liverpool, [3] York (UNITED KINGDOM)

09.15-09.25 **NIGHTTIME BLOOD PRESSURE ASSESSED USING HOME MONITORING IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES/ PREDIABETES: ASSOCIATION AND AGREEMENT WITHAMBULATORY MONITORING**
V. Ntousopoulos, A. Kollias, I. Bountzona, A. Destounis, A. Menti, A. Theodosiadi, K. Kyriakoulis, G.S. Stergiou
Athens (GREECE)

09.25-09.35 **SINGLE-PILL COMBINATION ANTIHYPERTENSIVE THERAPY IN HYPERTENSIVE, OBESE PATIENTS: A PROSPECTIVE, EPIDEMIOLOGICAL STUDY IN ROMANIA**
A.-M. Vintila, B. Dolofan, N. Trambitas, O. Vittos
Bucharest (ROMANIA)

09.35-09.45 **BLOOD PRESSURE VARIABILITY AND TARGET ORGAN DAMAGE INDICES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS**
I. Zarifis [1], A. Triantafyllou [2], B. Nikolaidou [2], A, Lazaridis [2], A. Malliora [2], S.-L. Papadopoulou [2], V. Kotsis [2], E. Gkaliagkousi [2]
[1] London (UNITED KINGDOM), [2] Thessaloniki (GREECE)

08.30-09.45 **ROOM III**

Oral Session 3

CHILDREN AND ADOLESCENTS

Chairpersons: D. Drozdz (Krakow, POLAND), E. Wühl (Heidelberg, GERMANY)

08.30-08.40 GLYCOSYLATED FIBRONECTIN AS A NOVEL PREDICTOR FOR THE MATERNAL AND FETAL COMPLICATIONS OF PREECLAMPSIA
A. Kluivers, R. Neuman, L. Saleh, W. Visser, J. Danser
Rotterdam (THE NETHERLANDS)

08.40-08.50 SIGNIFICANT INCREASES IN PERIPHERAL AND CENTRAL BLOOD PRESSURE IN CHILDREN AT MUCH LOWER BODY MASS INDEX THAN EXPECTED
L. Wilmsmeier, J. Von Der Born, R.I Sugianto, C. Grabitz, B. Mw Schmidt, A.C. Braun, D. Homeyer, U. Tegtbur, A. Melk
Hannover (GERMANY)

08.50-09.00 RISK FACTORS FOR CHRONIC HYPERTENSION 5 YEARS AFTER A PREGNANCY COMPLICATED BY PREECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
L. Voskamp, M. Rousian, J. J Koerts, R. Pm Steegers-Theunissen, A.J. Danser, K. Verdonk
Rotterdam (THE NETHERLANDS)

09.00-09.10 ASSOCIATION OF HYSTERECTOMY WITH HYPERTENSION INCIDENCE IN KOREAN WOMEN: A NATIONWIDE COHORT STUDY
B.-G. Kim, J.-S. Yuk, G.S.Kim, Y.S. Byun, M.-H.Kim, S.-H. Yoo
Seoul (SOUTH KOREA)

09.10-09.20 USING A MULTI-OMICS LANDSCAPE OF THE MATERNAL-FETAL INTERFACE TO MODEL THE LONGITUDINAL PATHOGENESIS OF EARLY-ONSET PRE-ECLAMPSIA
O. Nonn [1], O. Debnath [1], D. Valdes [1], A. Frolova [1], S. Haider [3], S. Verlohren [1], B. Thilaganathan [4], T.J. Kaituu-Lino [5], S. Tong [5], A.C. Staff [6], F. Coscia [1], D.N. Müller [1], R. Dechend [1], M. Gauster [2], N. Ishaque [1], F. Herse [1]
[1] Berlin (GERMANY),[2] Graz, [3] Vienna (AUSTRIA), [4] London (UNITED KINGDOM), [5] Melbourne (AUSTRALIA), [6] Oslo (NORWAY)

09.20-09.30 ASSOCIATIONS OF ULTRA LONG-TERM VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY SINCE CHILDHOOD WITH VASCULAR AGING IN MIDLIFE: A 30-YEAR PROSPECTIVE COHORT STUDY
Y. Wang [1], A.-M. Si [1], P. Zhao [1], C. Chu [1], M.-F. Du [1], D. Wang [1], H. Jia [1], G.-L. Hu [1], Q. Ma [1], Y. Yan [1], J. Chang [2], C. Delles [3], F.-Y. Chen [1], J.-J. Mu [1]
[1] Xi An (CHINA), [2] New Haven (USA), [3] Glasgow (UNITED KINGDOM)

09.30-09.45 MINI-LECTURE
Tasks and challenges in the transitioning of Adolescents into Adult Care
S. Stabouli (Thessaloniki, GREECE)

08.30-09.45 **CONVENTION HALL I D**

Pathway: Cardiovascular Renal Protection

CLINICAL CASES I

Chairpersons: M. El-Deeb (Oman, OMAN), E. Gkaliagkousi (Thessaloniki, GREECE)

08.30-08.55 **A case of hypertension due to polyarteritis nodosa**
D. Ferrão (Porto, PORTUGAL)

08.55-09.20 **An unusual case of renin-dependent hypertension**
T. Jansen (Amsterdam, THE NETHERLANDS)

09.20-09.45 **A 17-year-old patient with middle aortic syndrome**
J. Koziej (Warsaw, POLAND)

08.30-09.45 **HALL EUROPE**

Pathway: Hypertension and Clinical Practice Guidelines

WHY DO PEOPLE DEVELOP PRIMARY HYPERTENSION?

Chairperson: S. Laurent (Paris, FRANCE), K. Kario (Shimotsuke, JAPAN)

08.30-08.38 **It's all in the genes**
A.F. Dominiczak (Glasgow, UNITED KINGDOM)

08.38-08.46 **Individual lifestyle problems**
V. Cunha (Guimaraes, PORTUGAL)

08.46-08.54 **It's the environment**
M. Rajzer (Krakow, POLAND)

08.54-09.04 **Clearly sympathetic overdrive**
G. Grassi (Milan, ITALY)

09.04-09.12 **Obviously a small artery problem**
A. Virdis (Pisa, ITALY)

09.12-09.20 **Because of large artery stiffness**
T. Weber (Wels, AUSTRIA)

09.20-09.28 **It's the kidney, stupid!**
L. Vogt (Amsterdam, THE NETHERLANDS)

09.28-09.30 **Conclusions**

10.00-11.15 **CONVENTION HALL I D**

Pathway: Cardiovascular Renal Protection

Oral Session 4

HEART

Chairpersons: S. Masi (Pisa, ITALY), F. Zannad (Nancy, FRANCE)

10.00-10.10 LEFT VENTRICULAR GEOMETRIC PATTERNS AND TRIGLYCERIDE–GLUCOSE (TYG) INDEX
A. Paini, F. Bertacchini, C. Aggiusti, D. Stassaldi, S. Capellini, G. Buso, R. Gatta, M.L. Muiesan, M. Salvetti
Brescia (ITALY)

10.10-10.20 LEFT VENTRICULAR HYPERTROPHY AFTER RENAL TRANSPLANTATION: SYSTEMATIC REVIEW AND META-ANALYSIS
Z. Tian, K. Bergmann, J. Kaufeld, K. Schmidt-Ott, A. Melk, B. Schmidt
Hannover (GERMANY)

10.20-10.30 PREVALENCE AND PROGNOSTIC VALUE OF T-WAVE INVERSION IN HYPERTENSIVE PATIENTS: A 5-YEAR FOLLOW-UP STUDY
A. Kasiakogias, M. Stathoulopoulou, I. Leontsinis, C. Fragoulis, D. Konstantinidis, C. Fillipou, N. Karaminas, A. Nikolaou, P. Iliakis, S. Drogkaris, D. Polyzos, P. Tsioufis, E. Mantzouranis, D. Aragiannis, K. Tsioufis
Athens (GREECE)

10.30-10.40 ASSOCIATION BETWEEN BLOOD PRESSURE LEVELS AND COGNITIVE IMPAIRMENT IN PATIENTS WITH HEART FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS
F. Zhang, Y. Zhang, K. Zhang, X. Di, Jing Yu, F. Bai, Q. Wang
Lanzhou, Gansu (CHINA)

10.40-10.50 AGE-RELATED BURDEN OF ARRHYTHMIA AND ITS ASSOCIATION WITH AMBULATORY BLOOD PRESSURE PROFILES AND CARDIOVASCULAR RISK LEVELS: RESULTS FROM THE TEMPLAR PROJECT
K. Lundwall, T. Kahan, S. Omboni [2,3]
[1] Stockholm (SWEDEN), [2] Varese (ITALY), [3] Moscow (RUSSIA)

10.50-11.00 THE IMPORTANCE OF CARDIAC MAGNETIC RESONANCE IMAGING IN THE ASSESSMENT OF THE RISK OF CARDIAC ARRHYTHMIAS IN PATIENTS WITH ARTERIAL HYPERTENSION
A. Wysocki, P. Gac, R. Poreba, M. Michalek-Zrabkowska, K. Kraik, M. Poreba, H. Martynowicz, G. Mazur, B. Dziadkowiec-Macek, M. Fulek, P. Macek
Wroclaw (POLAND)

11.00-11.15 MINI-LECTURE
Ejection fraction still useful to guide Heart Failure Treatment?
S.E. Kjeldsen (Oslo, NORWAY)

10.00-11.15 **HALL EUROPE**

Pathway: Hypertension and Clinical Practice Guidelines

Oral Session 5

BEST ORAL ABSTRACT AWARD SESSION

Chairpersons: A. Coca (Barcelona, SPAIN), K. Kusche-Vihrog (Lübeck, GERMANY)

10.00-10.10 ASSOCIATION OF TOTAL MORTALITY AND CARDIOVASCULAR ENDPOINTS WITH THE TIMING OF THE FIRST AND SECOND SYSTOLIC PEAK OF THE AORTIC PULSE WAVE
Y.-B. Cheng [1], D.-W. An [1], L.S. Aparicio [2], Q.-F- Huang [1], Y. Li [1], J.A. Staessen [3]
[1] Shanghai (CHINA), [2] Buenos Aires (ARGENTINA), [3] Leuven (BELGIUM)

10.10-10.20 WHOLE GENOME SURVIVAL ANALYSIS OF 144,286 PEOPLE FROM UK BIOBANK IDENTIFIES NOVEL LOCI ASSOCIATED WITH BLOOD PRESSURE
S. Saluja [1], R. Darlay [2], J. Eales [1], M. Tomaszewski [1], R. Lennon [1], B. Keavney [1], A. Khanfar [1], P. Prestes [3], H. Cordell [2]
[1] Manchester, [2] Newcastle (UNITED KINGDOM), [3] Ballarat (AUSTRALIA)

10.20-10.30 CLINICAL SIGNIFICANCE OF NIGHTTIME BLOOD PRESSURE: EXPLORING THE ASSOCIATION OF NOCTURNAL HYPOTENSIVE PHENOTYPE AND HISTORY OF FALLS IN ELDERLY HYPERTENSIVE PATIENTS
A. Croce [1], G. Bilo [1], M.F. Pengo [1], A.M. Ornago [1,2], A. Ricco [1,2], G. Bellelli [1,2], G. Parati [1]
[1] Milan, [2] Monza (ITALY)

10.30-10.40 EFFECT OF ANTIHYPERTENSIVE DEPRESCRIBING ON SERIOUS ADVERSE EVENTS, MORTALITY, AND CARDIOVASCULAR DISEASE: LONG-TERM FOLLOW-UP OF THE OPTIMISE RANDOMISED CONTROLLED TRIAL
J. Sheppard [1], E. Temple [1], A. Wang [1], A. Smith [1], S. Pollock [1], G. Ford [1], R. Hobbs [1], N. Kenealy [1], M. Lown [2], S. De Lusignan [1], J. Mant [3], D. Mccartney [1], R. Payne [4], M. Williams [5], L.-M. Yu [1], R. Mcmanus [1]
[1] Oxford, [2] Southampton, [3] Cambridge, [4] Exeter, [5] London (UNITED KINGDOM)

10.40-10.50 GENOME-WIDE ASSOCIATION STUDY OF APPARENT TREATMENT-RESISTANT HYPERTENSION
T. Niiranen [1], A. Kauko [1], F. Vaura [2], J. Ebinger [3], D. Gordin [2], S.Cheng [3]
[1] Turku, [2] Helsinki (FINLAND), [3] Los Angeles (USA)

10.50-11.00 HYPERTENSIVE NEPHROPATHY: TRANSCRIPTOMICS OF KIDNEY BIOPSIES PREDICTS LONG TERM OUTCOME AND IDENTIFIES THERAPEUTIC TARGETS
T. Chen, J. Furriol [1], L. Zoe Landolt [1], S. Ivar Hallan [2,3], M. Altern Øvrehus [2,3], T. Knoop [1], A, Scherer [4], Ø. Eikrem [1], H.-P. Marti [1]
[1] Bergen, [2] Trondheim, [3] Trondheim, [4] Kontiolahti (FINLAND)

11.00-11.10 CARDIOVASCULAR RISK FACTORS HAVE DIFFERENT EFFECTS ON TOTAL BRAIN VOLUME AND CEREBRAL WHITE MATTER LESIONS OVER TIME: THE HELIUS STUDY
E.M.C. Vriend, A. De Sitter, T.A. Bouwmeester, O.H. Franco, H. Galenkamp, E.P. Moll Van Charante, D. Collard, A. Nederveen, B.-J.H. Van Den Born
Amsterdam (THE NETHERLANDS)

11.10-11.15 CONCLUSION

10.00-11.00 **ROOM II**

Mini-Symposium

supported by MENARINI GROUP

ESH GUIDELINES 2023: A NEW LIGHT ON BETA-BLOCKERS IN HYPERTENSION

Chairpersons: R. Kreutz (Berlin, GERMANY), G. Mancia (Milan, ITALY)

10.00-10.05 **Introduction**
G. Mancia (Milan, ITALY)

10.05-10.20 **Beta-blockers: a heterogeneous drug class under a new light**
K. Narkiewicz (Gdansk, POLAND)

10.20-10.35 **Nebivolol special characteristics: three decades of experience and future perspective**
C. Ferri (L'Aquila, ITALY)

10.35-10.50 **A case-based discussion: how to maximize Nebivolol clinical benefit in different patients' profiles**
P. van De Borne (Brussels, BELGIUM)

10.50-11.00 **Q&A and closing remarks**

10.00-11.00 **ROOM III**

Mini-Symposium

supported by SANOFI

INFLUENZA: IF YOU HAD A VACCINE TO PREVENT HEART ATTACKS!

Chairpersons: L. Hofstra (Utrecht, THE NETHERLANDS), M. Volpe (Rome, ITALY)

10.00-10.05 **Introduction**
M. Volpe (Rome, ITALY)

10.05–10.25 **All you need to know about influenza as a cardiologist**
A. Osterhaus (Hannover, GERMANY)

10.25-10.45 **Influenza as a trigger of cardiovascular complications and benefit of influenza vaccines**
L. Hofstra (Utrecht, THE NETHERLANDS)

10.45–11.00 **Q&A, Conclusion**
M. Volpe (Rome, ITALY)

10.00-10.45 **CONVENTION HALL I C**

Mini-Symposium

supported by SERVIER

REAL-LIFE HYPERTENSIVE PATIENTS: TOWARDS A HOLISTIC APPROACH IN CLINICAL PRACTICE

Chairpersons: C. Borghi (Bologna, ITALY), N. Ntusi (Cape Town, SOUTH AFRICA)

10.00-10.04 **Introduction**
C. Borghi (Bologna, ITALY)

10.04-10.16 **Should guidelines in hypertension be based on a holistic approach of patients?**
N. Ntusi (Cape Town, SOUTH AFRICA)

10.16-10.28 **Hypertension and diabetes: update on the management of hypertensive patients with diabetes**
A.-M. Vintila (Bucharest, ROMANIA)

10.28-10.40 **Hypertension and CAD: need of more SPCs**
S. Brouwers (Aalst, BELGIUM)

10.40-10.45 **Discussion and conclusion**
N. Ntusi (Cape Town, SOUTH AFRICA)

11.30-13.00 **CONVENTION HALL II**

Plenary Session 1

INTRODUCTION TO THE PATHWAYS OF ESH 2024

Chairpersons: J. Brguljan (Ljubljana, SLOVENIA), L.V. Halvorsen (Oslo, NORWAY), R. Kreutz (Berlin, GERMANY), G. Mancia (Milan, ITALY), R.E. Schmieder (Erlangen, GERMANY)

PART I - ESH Clinical Practice Guidelines

11.30-11.40 **Are they till evidence based?**
M. Brunström (Umea, SWEDEN)

11.40-11.50 **Why do we need them?**
R. de Pinho (Lisbon, PORTUGAL)

11.50-12.05 **Essentials of the 2024 ESH Clinical Practice Guidelines**
R. Kreutz (Berlin, GERMANY)

12.05-12.15 **Q&A**

PART II - Cardiovascular renal protection in 2024

12.15-12.33 **The concept**
F. Zannad (Nancy, FRANCE)

12.33-12.51 **Treatment perspectives**
H. Heerspink (Groningen, THE NETHERLANDS)

12.51-13.00 **Q&A**

13.15-14.00 **CONVENTION HALL I C**

Satellite Symposium

supported by SERVIER

WHY IS IT SO DIFFICULT TO REACH THE EXPECTED BP TARGET IN REAL-LIFE PATIENTS?

Chairpersons: H.-Y. Lee (Seoul, SOUTH KOREA), K. Narkiewicz (Gdansk, POLAND)

13.15-13.19 **Introduction**
H.-Y. Lee (Seoul, SOUTH KOREA)

13.19-13.31 **Treatment intensification to reach the target is key**
K. Narkiewicz (Gdansk, POLAND)

13.31-13.43 **Identifying and overcoming barriers to treatment intensification**
R. de Pinho (Lisbon, PORTUGAL)

13.43-13.55 **Triple SPCs remain largely underused: Can we do better?**
S. Masi (Pisa, ITALY)

13.55-14.00 **Discussion and Conclusion**
K. Narkiewicz (Gdansk, POLAND)

14.00-15.00 **HALL EUROPE**

Mini-Symposium

supported by OMRON HEALTHCARE EUROPE

DAY VERSUS NIGHT: NEW PERSPECTIVES ON STROKE PREVENTION USING HOME MONITORING TOOLS

Chairpersons: G. Parati (Milan, ITALY), G.S. Stergiou (Athens, GREECE)

14.00-14.20 **Importance of nocturnal blood pressure monitoring and systematic screening for atrial fibrillation**
G. Parati (Milan, ITALY)

14.20-14.40 **Silent Surges: Unravelling the Impact of Nocturnal Blood Pressure Fluctuations**
M. Pengo (Milan, ITALY)

14.40-15.00 **New tools for atrial fibrillation screening**
G.S. Stergiou (Athens, GREECE)

14.00-15.15 **ROOM II**

Symposium

supported by MERCK

BETA-BLOCKERS IN HYPERTENSION AND CVD: SIMILAR OR DIFFERENT?

Chairpersons: G. Grassi (Milan, ITALY), G. Mancia (Milan, ITALY)

14.00-14.25 **Hypertension and beta-blocker choice: influence of age, stress, and co-morbidities**
S.E. Kjeldsen (Oslo, NORWAY)

14.25-14.50 **Chronic coronary artery disease and beta-blockers: update of latest evidence**
R. Fontes-Carvalho (Vila Nova de Gaia, PORTUGAL)

14.50-15.15 **Heart failure and beta-blockers: initiation and continuation**
M. Tokmakova (Plovdiv, BULGARIA)

14.00-15.00 **ROOM III**

Mini-Symposium

supported by RECOR MEDICAL

TRUE RESISTANT HYPERTENSION TREATMENT IN 2024

Chairperson: C. Delles (Glasgow, UNITED KINGDOM)

14.00-14.02 **Introduction**
C. Delles (Glasgow, UNITED KINGDOM)

14.02-14.12 **True resistant hypertension: diagnostics & treatment options**
C. Delles (Glasgow, UNITED KINGDOM)

14.12-14.32 **Renal Denervation as a third pillar therapy option: What have we learned? Where are we going?**
Introduction: A. Pathak (Monaco, FRANCE)

Speakers: D. Hering (Gdansk, POLAND),
M. Joner (Munich, GERMANY)

14.32-15.00 **ROUNDTABLE**
Patient Care Pathways from Hypertension specialists to Interventionalists
Chairperson: A. Pathak (Monaco, FRANCE)

14.32-14.44 **From patient selection to treatment and follow-up in daily practice**
D. Hering (Gdansk, POLAND), M. Joner (Munich, GERMANY)

14.44-14.57 **How to we improve patient care for uncontrolled and true resistant HTN patients?**
D. Hering (Gdansk, POLAND), M. Joner (Munich, GERMANY)

14.57-15.00 **Conclusion**
C. Delles (Glasgow, UNITED KINGDOM)

14.00-15.15 **CONVENTION HALL I D**

Pathway: Cardiovascular Renal Protection

ESH - ERA JOINT SESSION

Chairpersons: H. Heerspink (Groningen, THE NETHERLANDS), P. Sarafidis (Thessaloniki, GREECE)

14.00-14.20 **KEY NOTE LECTURE: Hypertensive nephropathy- does it exist?**
B. Freedman (Wake Forest, NC, USA)

14.20-14.40 **RASi, SGLT2, nsMRA and GLP1A: all in? And how?**
C. Wanner (Wurzburg, GERMANY)

14.40-15.00 **New biomarkers guiding managing of CKD**
A. Van Craenenbroeck (Leuven, BELGIUM)

15.00-15.15 **Q&A**

14.15-15.15 **CONVENTION HALL I C**

Mini-Symposium

Organised by Radcliffe Medical kindly supported by AstraZeneca.

UNLOCKING THE CHALLENGES OF UNCONTROLLED HYPERTENSION

Chairperson: T. Weber (Wels, AUSTRIA)

Clinical Impact of Uncontrolled Hypertension and Case Presentation

14.15-14.20 **Case study presentation**
B. Williams (London, UNITED KINGDOM)

14.20-14.30 **Discussion**
E. Jones (Cape Town, SOUTH AFRICA), T. Weber (Wels, AUSTRIA), B. Williams (London, UNITED KINGDOM)

14.30-14.40 **Current treatment barriers and limitations**
E. Jones (Cape Town, SOUTH AFRICA), T. Weber (Wels, AUSTRIA), B. Williams (London, UNITED KINGDOM)

14.40–14.45 **Discussion**
E. Jones (Cape Town, SOUTH AFRICA), T. Weber (Wels, AUSTRIA), B. Williams (London, UNITED KINGDOM)

14.45-15.05 **What drives uncontrolled hypertension?**
E. Jones (Cape Town, SOUTH AFRICA)

15.05-15.15 **Q&A**

15.45-17.00 **CONVENTION HALL I C**

Oral Session 6

BLOOD PRESSURE MEASUREMENT 1

Chairpersons: A. Odili (Abujanger, NIGER), E. Rodilla Sala (Valencia, SPAIN)

15.45-16.00 **MINI-LECTURE**
How and when to use ABPM IN Hypertensive Adolescents?
E. Wühl (Heidelberg, GERMANY)

16.00-16.10 **MAY MEASUREMENT MONTH 2023 IN CROATIA, CLOSE TO GUINNESS RECORD**
B. Jelakovic, A. Soldo, O. Velkovski Skopic, I. Abramovic, A. Jelakovic, J. Josipovic, V. Bralic Lang, M. Mihalic, M. Domislovic, K. Capak, M. Bubas
Zagreb (CROATIA)

16.10-16.20 **PERSONAL BLOOD PRESSURE VARIABILITY IS NOT ASSOCIATED WITH SEASONAL BLOOD PRESSURE EFFECTS: A 4-YEAR PROSPECTIVE COHORT OF 1,151 PARTICIPANTS FROM ELDERLY CENTRES IN HONG KONG**
K. Kf Tsoi, Z. Hao, Y. Chen, H.H. Chan, K. Kl Yiu
Shatin (HONG KONG)

16.20-16.30 **ASSOCIATION OF CARDIOVASCULAR RISK AMONG DIFFERENT COMMON OFFICE BLOOD PRESSURE MEASUREMENT PROTOCOLS IN COMMUNITY-BASED CHINESE POPULATION**
J. Yong, F. Fan, J. Li, Y. Zhang
Beijing (CHINA)

16.30-16.40 **INCREASED BLOOD PRESSURE VARIABILITY AND DECREASED HEART RATE VARIABILITY IN OLDER VS. YOUNGER INDIVIDUALS: MARKERS OF DISTURBED CARDIOVASCULAR AUTONOMIC MODULATION WITH AGEING?**
M.S. Stoenoiu [1], Y. Zhao [2], Z.-Y. Zhang [2,3], M. Lopez-Sublet [1,4], N.-G. Manolache [1], J. Zhang [2], A. Pasquet [1], V. Varnavas [1], C. Beauloye [1], G. Parati [5], G.S. Stergiou [6], A. Persu [1]
[1] Brussels, [2] Leuven (BELGIUM), [3] Oxford (UNITED KINGDOM), [4] Bobigny, Paris (FRANCE), [5] Milan (ITALY), [6] Athens (GREECE)

16.40-16.50 **FEASIBILITY OF WATCH-TYPE CUFF-LESS BLOOD PRESSURE MEASUREMENT DEVICE IN DAILY BLOOD PRESSURE MONITORING**
Y. Lee, J. Seo, H. Lee
Seoul (SOUTH KOREA)

16.50-17.00 **ISOLATED SYSTOLIC HYPERTENSION OF YOUTH – FINDINGS FROM THE I24ABC CONSORTIUM**
K. Danninger [1], T. Weber [1], S. Wassertheurer [2], A. Protogerou [3], J.E. Sharman [4], E. Rodilla Sala [5], I. Wilkinson [6], B. Hametner [2], S. Ortner [2], C. Mayer [2], Y. Li [7], J.M. Pascual [5], A, Argyris [3], E. Athanasopoulou [3], F. Karachalias [3], C. McEniery [6], G.S. Stergiou [3], M.A. Mota Gomes [8], B. McDonnell [9]
[1] Wels, [2] Vienna (AUSTRIA), [3] Athens (GREECE), [4] Tasmania (AUSTRALIA), [5] Valencia (SPAIN), [6] Cambridge (UNITED KINGDOM), [7] Shanghai (CHINA), [8] Alagoas (BRAZIL), [9] Cardiff (UNITED KINGDOM)

15.45-17.00 **ROOM II**

Oral Session 7

SECONDARY HYPERTENSION AND DIAGNOSTIC PROCEDURES

Chairpersons: D. Lovic (Belgrade, SERBIA),
J. Widimsky (Prague, CZECH REPUBBLIC)

15.45-15.55 LONG-TERM FOLLOW-UP OF PATIENTS WITH HIGH ALDOSTERONE-TO-RENIN RATIO BUT NEGATIVE CONFIRMATORY TEST FOR PRIMARY ALDOSTERONISM
F. Buffolo [1], A. Pecori [1], M. Reincke [2], M. Outland [2], F. Veglio [1], P. Schwarzlmüller [2], M. Bidlingmaier [2], S. Kunz [2], C. Stremmel [2], G. Mengozzi [1], G. Priolo [1], P. Mulatero [1], C. Adolf [2], S. Monticone [1]
[1] Turin (ITALY), [2] München (GERMANY)

15.55-16.05 MICROWAVE TISSUE DIGESTION AND FLAME ATOMIC ABSORPTION SPECTROSCOPY FOR MEASURING TISSUE SODIUM CONTENT IN HYPERTENSIVE AND CARDIOVASCULAR RISK PATIENTS
R. Van Duin [1], J.J. Oppelaar [1], A.G.U. Heisel [1], A. Akua Kromo Annor [1], R. Wouda [1], K. Van Zuilen [1], D. M.P. Naessens [1], J. De Vos [1], E. Ntp Bakker [1], M. Hagner [2], F. Conradt [2], R.H. Olde Engberink [1], L. Vogt [1]
Amsterdam (THE NETHERLANDS)

16.05-16.15 MYOCARDIAL MECHANO-ENERGETIC EFFICIENCY CHANGES IN PRIMARY ALDOSTERONISM PATIENTS
M.L. Muiesan, D. Stassaldi, S. Capellini, C. Agabiti Rosei, F. Bertacchini, C. Aggiusti, M. Salvetti, A. Paini, C. De Ciuceis, M. Dusi, R. Camossi, S. Ghignatti, G. Buso
Brescia (ITALY)

16.15-16.25 THE EFFECT OF TREATMENT ON THE INFLAMMATION PROFILE AMONG PATIENTS WITH PRIMARY ALDOSTERONISM
M. Kantauskaite, B. Duvnjak, C. Schmidt, E. Königshausen, U. Zierhut, L.C. Rump, J. Stegbauer
Düsseldorf (GERMANY)

16.25-16.35 LONG-TERM CLINICAL OUTCOME OF PHYSIOLOGY-GUIDED RENAL ARTERY STENTING WITH ZETAROLIMUS ELUTING STENTS IN PATIENTS WITH UNCONTROLLED RENOVASCULAR HYPERTENSION
V. Galli, L. Trento, F. Salfa, S. Fezzi, A. Trevisanello, E. Galuppi, M. Casal, M. Piscopo, R. Scarsini, G. Pesarini, A. Gambaro, V. Ferrero, D. Tavella, F.L. Ribichini
Verona (ITALY)

16.35-16.45 COMPARISON OF CENTRAL SYSTOLIC BLOOD PRESSURE (CSBP) ESTIMATED BY DIRECT CENTRAL BLOOD PRESSURE (DCBP) FORMULA AND RADIAL TONOMETRY BY SPIGMOCOR: AN INVASIVE VALIDATION STUDY
D. Leone, F. Vallelonga, G. Bruno, S. Fragapani, M. Cesareo, L. Airale, G. Mingrone, A. Milan
Turin (ITALY)

16.45-17.00 MINI-LECTURE
The advanced Neuroimaging in Hypertension: translational tools to map the pattern of Cerebral Injury
L. Carnevale (Pozzilli, ITALY)

15.45-16.45 **ROOM III**

Mini-Symposium

supported by NOVO NORDISK

CONTROLLING THE UNCONTROLLABLE - RESISTANT HYPERTENSION AND THE ROLE OF ALDOSTERONE

Chairpersons: M. Azizi (Paris, FRANCE), R.E. Schmieder (Erlangen, GERMANY)

15.45-15.55 **Aldosterone - a major cause of cardiovascular and renal damage in arterial hypertension**
M. van der Giet (Berlin, GERMANY)

15.55-16.00 **Discussion**

16.00-16.10 **Overcoming the resistance - Drug therapies for treating resistant hypertension**
J. Stegbauer (Dusseldorf, GERMANY)

16.10-16.15 **Discussion**

16.15-16.25 **Overcoming the resistance - Is renal denervation the solution?**
K. Tsioufis (Athens, GREECE)

16.25-16.30 **Discussion**

16.30-16.40 **Aldosterone receptor blocker versus aldosterone synthase inhibitor - Who is more effective in blocking aldosterone?**
M. Azizi (Paris, FRANCE)

16.40-16.45 **Discussion**

15.45-17.00 **CONVENTION HALL I D**

Pathway: Cardiovascular Renal Protection

Chairperson: J. Redon (Valencia, SPAIN), S. Stabouli (Thessaloniki, GREECE)

15.45-16.05 **KEY NOTE LECTURE**
Albuminuria a risk marker of what: kidney or vasculature? And how to measure?
R. Gansevoort (Groningen, THE NETHERLANDS)

DEBATE
Albuminuria in 2024 – An accepted surrogate marker of treatment success?

16.05-16.15 **PRO**
P. Sarafidis (Thessaloniki, GREECE)

16.15-16.18 **Discussion**

16.18-16.28 **CON**
G.F. Strippoli (Bari, ITALY)

16.28-16.30 **Discussion**

16.30-16.45 **Q&A**

16.45-17.00 **Pitfall in GFR estimation**
P. Delanaye (Liege, BELGIUM)

15.45-17.00 **HALL EUROPE**

Pathway: Hypertension and Clinical Practice Guidelines

OPTIONS AND CHALLENGES FOR SUCCESSFUL GLOBAL GUIDELINES IMPLEMENTATION

Chairpersons: G. Mancia (Milan, ITALY),
B. Williams (London, UNITED KINGDOM)

15.45-16.45 **International expert Podium statement**
M. El-Deeb (Muscat, OMAN),
K. Kario (Shimotsuke, JAPAN),
P. Lopez-Jaramillo (Bucaramanga, COLOMBIA),
N. Ntusi (Cape Town, SOUTH AFRICA),
A. Odili (Abuja, NIGER),
V. Ram (Hyderabad, INDIA),
A.E. Schutte (Sidney, AUSTRALIA),
J. Shin (Seoul, SOUTH KOREA),
J.-G. Wang (Shanghai, CHINA),
S. Whelton (Maryland, USA)

16.45-17.00 **Final Discussion**

17.15-18.15 **CONVENTION HALL I C**

Oral Session 8

RESISTANT HYPERTENSION AND DEVICE-BASED THERAPY

Chairpersons: R. Gómez Huelgas (Malaga, SPAIN),
M. Tomaszewski (Manchester, UNITED KINGDOM)

17.15-17.25 **POOLED, LONG-TERM ANALYSIS OF THE GLOBAL SYMPLICITY CLINICAL TRIAL PROGRAM OF RADIOFREQUENCY RENAL DENERVATION FOR THE TREATMENT OF UNCONTROLLED HYPERTENSION**
R. Whitbourn [5], D.L. Bhatt [6], G. Bakris [7], K. Kario [8], M. Fahy [9], M. Böhm [1]
[1] Homburg (GERMANY), [2] Philadelphia (USA), [3] Milan (ITALY), [4] Atlanta (USA), [5] Melbourne (AUSTRALIA), [6] New York (USA), [7] Chicago (USA), [8] Tochigi (JAPAN), [9] Santa Rosa (USA)

17.25-17.35 **THREE-YEAR NIGHTTIME BLOOD PRESSURE REDUCTIONS AFTER RADIOFREQUENCY RENAL DENERVATION IN PATIENTS WITH UNCONTROLLED HYPERTENSION AND CHRONIC KIDNEY DISEASE**
M. Schlaich [1], F. Mahfoud [2], K. Narkiewicz [3], L. Ruilope [4], B. Williams [5], R.E. Schmieder [6], G. Mancia [7], F. Sharif [8], F. Ribichini [9], M. Fahy [10], M. Böhm [2]
[1] Perth (AUSTRALIA), [2] Homburg (GERMANY), [3] Gdansk (POLAND), [4] Madrid (SPAIN), [5] London (UNITED KINGDOM), [6] Erlangen (GERMANY), [7] Milan (ITALY), [8] Galway (IRELAND), [9] Verona (ITALY), [10] Santa Rosa (USA)

17.35-17.45 **PROGNOSIS OF RESISTANT HYPERTENSION IN KOREAN HYPERTENSIVE PATIENTS: A NATIONWIDE OBSERVATIONAL COHORT STUDY**
C. Joo Lee [1], H. Kyu Lee [1], J. Seo [1], D. Kang [2], J. Hwang [2], S. Park [1], W. Bum Pyun [1]
[1] Seoul, [2] Gyeongsan (SOUTH KOREA)

17.45-17.55 **RENAL DENERVATION AT THE GEORGES-POMPIDOU EUROPEAN HOSPITAL IN PARIS: THE TRANSITION FROM RESEARCH TO STANDARD CARE IN HYPERTENSIVE PATIENTS**
N. Gebara, M. Al Ahmar, A. Lorthioir, J. Mallart-Riancho, L. Amar, M. Sapoval, M. Azizi
Paris (FRANCE)

17.55-18.05 **A NOVEL ELECTRO-HYDRAULIC ACOUSTIC THERAPY REDUCES BLOOD PRESSURE IN HYPERTENSIVE PATIENTS WITH CHRONIC KIDNEY DISEASE: 12-MONTH FOLLOW-UP**

T. Wolak [1], A. Lerman [2], M. Glikson [1], I. Sukholutsky [1], S. Silberman [1], L. Lerman [2]
[1] Jerusalem (ISRAEL), [2] Rochester (USA)

18.05-18.15 **TREAT TRIAL: MULTI-CENTER CROSS-SECTIONAL TREATMENT EVALUATION OF APPARENT RESISTANT HYPERTENSION IN BELGIUM**

S. Brouwers [1,2], J. Huart [3], M. Chabot [2], B. Van Nieuwenhuyse [2], D. Munhoz [1,4]
[1] Aalst, [2] Brussels, [3] Liège (BELGIUM), [4] Naples (ITALY)

17.15-18.15 **ROOM III**

Oral Session 9

BLOOD PRESSURE MEASUREMENT 2

Chairpersons: Z. Jarai (Budapest, HUNGARY),
T. Sheppard (Oxford, UNITED KINGDOM)

17.15-17.25 **THE PROGNOSTIC POWER OF DIASTOLIC-TO-SYSTOLIC ARTERIAL STIFFENING IS GREATER AT NIGHTTIME IN MIDDLE-AGE PATIENTS UNDERGOING 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING**

B. Gavish [1], A. De La Sierra [2], M. Bursztyn [1], L. M Ruilope [3], B. Williams [4]
[1] Jerusalem (ISRAEL), [2] Terressa, [3] Madrid (SPAIN), [4] London (UNITED KINGDOM)

17.25-17.35 **OUTCOME-DERIVED DIAGNOSTIC THRESHOLD FOR CENTRAL BLOOD PRESSURE BASED ON CARDIOVASCULAR RISKS USING UK BIOBANK**

S. Wang, S. Ys Wong, B. Hk Yip, E. Kp Lee
Shatin (HONG KONG)

17.35-17.45 **APPLICATION OF PHOTO RECOGNITION TO ENCOURAGE PARTICIPATION IN HOME BLOOD PRESSURE MONITORING: A COMMUNITY COHORT OF 18,867 USERS IN HONG KONG**

K. Kf Tsoi, Z. Hao, Y. Chen, H. H Chan, D. Mt Tsang, K. K. Yiu
Shatin (HONG KONG)

17.45-17.55 **DAY-TO-DAY REPRODUCIBILITY OF NOCTURNAL BLOOD PRESSURE FALL (DIPPING) EVALUATED WITH WEARABLE AND HOME DEVICES IN HYPERTENSIVE PATIENTS**

M. Pengo, A. Croce, E. Brenna, D. Soranna, E. Gianfranceschi, E. Nardin, D. Rosa, C. Lombardi, G. Bilo, A. Zambon, G. Parati
Milan (ITALY)

17.55-18.05 ASSESSMENT OF THE CART-I PLUS FOR CUFFLESS BLOOD PRESSURE MONITORING: A COMPARATIVE STUDY WITH STANDARD ABPM ACROSS DIVERSE PATIENT SUBGROUPS

H. Lee, H -Y. Lee
Seoul (SOUTH KOREA)

18.05-18.15 REPRODUCIBILITY OF NIGHT-TIME BLOOD PRESSURE PHENOTYPES. RESULTS FROM THE HARVEST

P. Palatini [1], F. Saladini [1], L. Mos [2], O. Vriz [2], A. Mazzer [3], G. Zanata [4], C. Fania [1], M. Rattazzi [1]
[1] Padua, [2] San Daniele del Friuli, [3] Vittorio Veneto, [4] Sacile (ITALY)

17.15-18.15 **CONVENTION HALL I D**

Pathway: Cardiovascular Renal Protection

TARGET BLOOD PRESSURE CONTROVERSIES

Chairperson: M. L. Muiesan (Brescia, ITALY), K. Tsioufis (Athens, GREECE)

17.15-17.27 **Target BP controversies in LVH**
S.E. Kjeldsen (Oslo, NORWAY)

17.27-17.39 **Target BP controversies in CKD**
P. Sarafidis (Thessaloniki, GREECE)

17.39-17.51 **Target BP controversies in Diabetes**
M. Brunström (Umeå, SWEDEN)

17.51-18.03 **Out of office targets?**
G.S. Stergiou (Athens, GREECE)

18.03-18.15 **Final Discussion**

17.15-18.15 **HALL EUROPE**

Pathway: Hypertension and Clinical Practice Guidelines

ESH - EFIM JOINT SESSION: PATIENT EVALUATION AND RISK ASSESSMENT

Chairpersons: R. Gómez Huelgas (Malaga, SPAIN), A. Manolis (Athens, GREECE)

17.15-17.30 **What is essential and feasible? - EFIM perspective**
E. Rodilla Sala (Valencia, SPAIN)

17.30-17.45 **What is essential and feasible? - ESH perspective**
R. de Pinho (Lisbon, PORTUGAL)

17.45-18.15 **Podium Discussion with ESH and EFIM members**
M. Arici (Ankara, TURKEY), M. Camafort (Barcelona, SPAIN), D. Hering (Gdansk, POLAND), A. Kasiakogias (Athens, GREECE), H. Ribeiro (Santa Maria da Feira, PORTUGAL)

17.15-18.15 **ROOM II**

Mini-Symposium

supported by AXELIFE

NEW APPROACH FOR ARTERIAL STIFFNESS ASSESSMENT - THE POPMETER DEVICE

Chairpersons: R. Asmar (Paris, FRANCE), P. Boutouyrie (Paris, FRANCE)

17.15-17.30 **The importance of arterial stiffness**
P. Boutouyrie (Paris, FRANCE)

17.30-17.35 **Discussion**

17.35-17.50 **The pOpmeter device**
S. Zanelli (Paris, FRANCE)

17.50-17.55 **Discussion**

17.55-18.10 **Clinical applications of the pOpmeter device**
A. Pathak (Monaco, FRANCE)

18.10-18.15 **Discussion**

16.00-18.30 **ROOM VII**

SEMINAR für Hypertensiologinnen/ Hypertensiologen DHL®

Tagungsleiter: M. van der Giet (Berlin, GERMANY),
F. Limbourg (Hannover, GERMANY)

16.00–16.05 **Begrüßung**
M. van der Giet (Berlin, GERMANY)

16.05–16.45 **Epidemiologie und Pathophysiologie der Hypertonie**
M. van der Giet (Berlin, GERMANY)

16.45–17.25 **Basisdiagnostik bei Hypertonie mit Blutdruckmessung incl. ABDM und zentralem Blutdruck**
F. Limbourg (Hannover, GERMANY)

17.25–17.30 **Pause**

17.30–18.30 **Diagnostik bei sekundären Hypertonieformen**
C. Ott (Nürnberg, GERMANY)

18.30-20.00 **EXHIBITION AREA**

Moderated E-poster Session 1

TOTEM T01 Epidemiology
TOTEM T02 Blood Pressure Measurement
TOTEM T03 Kidney
TOTEM T04 and T05 Heart, Brain, Vascculature
TOTEM T06 Risk factors
TOTEM T07 Clinical Studies
TOTEM T08 Secondary HTN and Diagnostic procedures
TOTEM T09 Children, Adolescents, Women
TOTEM T10 Diabetes, Obestiy, Comorbidities
TOTEM T11 Device Based Therapy, Resistant Hypertension, Adherence
TOTEM T12 Hypertension Phenotypes, Older Persons
TOTEM T13 Pharmacotherapy and Lifestyle interventions
TOTEM T14 Pathophysiology, Genomics
TOTEM T15 General hypertension research
TOTEM T16 Best Poster Awards

33rd

EUROPEAN MEETING

ON HYPERTENSION
AND CARDIOVASCULAR
PROTECTION

SCIENTIFIC PROGRAMME

SUNDAY, JUNE 2

08.00-10.30 **Room VII**

SEMINAR für Hypertensiologinnen/ Hypertensiologen DHL®

08.00–08.05 **Begrüßung**
F. Limbourg (Hannover, GERMANY)

08.05–08.45 **Therapie der arteriellen Hypertonie – Lebensstiländerungen**
J. Stegbauer (Düsseldorf, GERMANY)

08.45–09.45 **Therapie der arteriellen Hypertonie – Pharmakotherapie und Interventionen**
M. van der Giet (Berlin, GERMANY)

09.45–09.50 **Pause**

09.50–10.30 **Daten und Strategien zur Patientenmotivation**
J. Jordan (Cologne, GERMANY)

07.15-08.15 **ROOM III**

Morning Session

HYPERTENSION IN BLACK AFRICANS

Chairpersons: N. Ntusi (Cape Town, SOUTH AFRICA), A. Persu (Brussels, BELGIUM)

07.15-07.19 **Introduction**
A. Persu (Brussels, BELGIUM)

07.19-07.29 **What is different about hypertension in black Africans?**
E. Ogola (Nairobi, KENYA)

07.29-07.39 **What is the evidence base for appropriate management of hypertension in black Africans?**
E. Jones (Cape Town, SOUTH AFRICA)

07.39-07.47 **May Measurement Month as a tool to improve blood pressure awareness and management in Africa**
N.R. Poulter (London, UNITED KINGDOM)

07.47-07.57 **What are the gaps in practice and how can the guidelines take a more inclusive approach?**
K. Narkiewicz (Gdansk, POLAND)

07.57-08.09 **Panel Discussion**

08.09-08.15 **Closing remarks**
N. Ntusi (Cape Town, SOUTH AFRICA)

08.30-09.45 **CONVENTION HALL I C**

Oral Session 10

CLINICAL STUDIES

Chairpersons: R. Gansevoort (Groningen, THE NETHERLANDS), F. Mahfoud (Hamburg, GERMANY)

08.30-08.45 **MINI-LECTURE**
Microbiome: still relevant for CV Health after the initial enthusiasm?
T. Niiranen (Turku, FINLAND)

08.45-08.55 **EPLERENONE VS IRBESARTAN AS FIRST LINE THERAPY IN OBESE HYPERTENSIVE PATIENTS: PRELIMINARY RESULTS OF HEBRO TRIAL IN AMBULATORY BLOOD PRESSURE MEASUREMENTS**
P. Iliakis, S. Drogkaris, M. Kouremeti, E. Siafi, F. Tatakis, M. Stathoulopoulou, E. Manta, I. Kachrimanidis, A. Sakalidis, P. Tsioufis, N. Karaminas, I. Liatakis, K. Dimitriadis, C. Thomopoulos, A. Kasiakogias, D. Konstantinidis, K. Tsioufis
Athens (GREECE)

08.55-09.05 **SYNERGIA-MOROCCO: EFFECTIVENESS OF HYPERTENSION MANAGEMENT WITH AN AMLODIPINE AND PERINDOPRIL ARGININE-BASED STRATEGY IN MOROCCO: STUDY DESIGN AND PRELIMINARY DATA**
S.S. El Khayat [1], C. Maadjhou Mba [2], A. Mbanya [2], J.-C. Mbanya [2], M. El Ghali Benouna [2]
[1] Casablanca (MOROCCO), [2] Yaoundé (CAMEROON)

09.05-09.15 **BLOOD PRESSURE CONTROL WITH APROCITENTAN IN RESISTANT HYPERTENSION**
K. Narkiewicz [1], P. Danaietash [2], G. Kania [3], I. Kantola [4], F. Martinez-Garcia [5], M. Sassi-Sayadi [6], M.P. Schlaich [2], N. Toursarkissian [7], J.-G. Wang [8], M.A Weber [9], A. Gimona [2]
[1] Gdansk (POLAND), [2] Allschwil (SWITZERLAND), [3] Skierniewice (POLAND), [4] Turku (FINLAND), [5] Valencia (SPAIN), [6] Perth (AUSTRALIA), [7] Berlin (GERMANY), [8] Shanghai (CHINA), [9] Brooklyn (USA)

09.15-09.25 **CARDIAC TROPONIN-T AND N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE RELATED TO OTHER CLINICAL HIGH-RISK FACTORS IN PATIENTS ON AT LEAST TWO ANTIHYPERTENSIVE AGENTS**
A.C. Larstorp [1], L.V. Halvorsen [1], O.F. Hoff [1], C.L Soraas [1], V.N. Kjaer [1], A. Aune [2], E. Olsen [3], K.M. Brobak [4], O.U. Bergland [1], S. Rognstad [1], E. Gerdts [2], R. Mo [3], M. Solbu [4], M.S. Opdal [1], S.E. Kjeldsen [1], M. Rostrup [1], A. Hoieggen [1]
[1] Oslo, [2] Bergen, [3] Trondheim, [4] Tromsø (NORWAY)

09.25-09.35 **ACHIEVED SYSTOLIC BLOOD PRESSURE BELOW 130 MMHG PRESERVES KIDNEY FUNCTION IN HIGH-RISK HYPERTENSIVE PATIENTS WITHOUT CARDIAC HYPERTROPHY BUT WITH PROTEINURIA**
E. Olsen [1], C. Soraas [2], R.E. Schmieder [3], K. Jamerson [4], T.Macdonald [5], G. Mancia [6], S. Heimark [2], M.H. Mehlum [2], J. Mariampullai [2], K. Liestol [2], A.C. Larstorp [2], A. Hoieggen [2], S.E. Kjeldsen [2], M. Rostrup [2], R. Mo [1], S. Julius [4], M.A. Weber [7]
[1] Trondheim, [2] Oslo (NORWAY), [3] Erlangen (GERMANY), [4] Ann Arbor (USA), [5] Dundee (UNITED KINGDOM), [6] Milan (ITALY), [7] New York (USA)

09.35-09.45 **WHY HAPPENS A PROGRESSIVE DECREASE OF BLOOD PRESSURE AFTER RENAL DENERVATION**
A. Bosch [1], A. Schmid [1], D. Kannenkeril [1], J. Harazny [2], C. Ott [1,3], K. Striepe [1], M. Guenes-Altan [1], Hannah Roth [1], M. Schiffer [1], M. Uder [2], R.E. Schmieder [1]
[1] Erlangen (GERMANY), [2] Warmia (POLAND), [3] Nuremberg (GERMANY)

08.30-09.45 **ROOM II**

Oral Session 11

RISK FACTORS

Chairpersons: P. van de Borne (Brussels, BELGIUM), W. Wojciechowska (Krakow, POLAND)

08.30-08.40 BLOOD PRESSURE AND RENAL FUNCTION RESPONSES IN WORKERS EXPOSED TO LEAD FOR UP TO SIX YEARS
Y. Yu [1], D. An [1], W. Yang [2], P. Verhamme [1], K. Allegaert [1], T. Nawrot [1], J. Staessen [4]
[1] Leuven (BELGIUM), [2] Shanghai (CHINA), [4] Mechelen (BELGIUM)

08.40-08.50 THE INTERACTION BETWEEN GLOMERULAR FILTRATION RATE (GFR)-ADJUSTED URICEMIA AND INSULIN RESISTANCE IN PREDICTING MORTALITY: THE URRAH PROJECT
E. Russo [1], F. Viazzi [1], R. Pontremoli [1], E. Casiglia [2], G. Desideri [3], L. D'Elia [4], C. Ferri [3], F. Galletti [4], M. Masulli [4], M.L. Muiesan [5], V. Tikhonoff [2], A. Virdis [6], G. Grassi [7], C. Borghi [8], Siia Working Group [8]
[1] Genoa, [2] Padua, [3] L'Aquila, [4] Naples, [5] Brescia, [6] Pisa, [7] Monza, [8] Bologna (ITALY)

08.50-09.00 CALCIUM INTAKE IS INVERSELY ASSOCIATED WITH PERIPHERAL BLOOD PRESSURE: POSSIBLE INTERACTION WITH SERUM CALCIUM
C. Dal Pont [1], A. Giontella [1,2], A. Sartorio [1], P. Minuz [1], U. Ericson [2], O. Melander [2], C. Fava [1,2]
[1] Verona (ITALY), [2] Malmö (SWEDEN)

09.00-09.10 LONG-TERM SYSTOLIC BLOOD PRESSURE VARIABILITY AS AN INDEPENDENT RISK FACTOR FOR CARDIOVASCULAR EVENTS IN KIDNEY TRANSPLANT RECIPIENTS
D. Picciotto, E. Bussalino, L. Macciò, A. Parodi, M. T. Gandolfo, F. Viazzi
Genoa (ITALY)

09.10-09.20 HEALTHY METABOLIC STATUS: HOW FREQUENT IS THE TRANSITION TO A METABOLICALLY UNHEALTHY PHENOTYPE?
P. Palatini [1], F. Saladini [1], L. Mos [2], O. Vriz [2], A. Mazzer [3], G.Garavelli [4], G. Berton [5], M. Rattazzi [1]
[1] Padua, [2] San Daniele del Friuli, [3] Vittorio Veneto, [4] Cremona, [5] Conegliano (ITALY)

09.20-09.30 RESTING HEART RATE AND MORTALITY RISK IN HYPERTENSIVE PATIENTS WITH NO ATRIAL FIBRILLATION
A. Pittaras [1], P. Kokkinos [2,3], C. Faselis [2], C. Grassos [1], M. Doumas [2], E. Kallistratos [2], A. Manolis [2], I. Babu Samuel [2]
[1] Athens (GREECE), [2] Washington, DC (USA), [3] New Brunswick, NJ (USA)

09.30-09.45 MINI-LECTURE
How to prevent dementia in hypertensive patients
D. Hering (Gdansk, POLAND)

08.30-09.45 **ROOM III**

Oral Session 12

KIDNEY

Chairpersons: B. Freedman (Wake Forest, USA), L.V. Halvorsen (Oslo, NORWAY)

08.30-08.45 **MINI-LECTURE**
Lymphatics and fluid homeostasis in hypertension
G. Rossitto (Padua, ITALY)

08.45-08.55 **COMPUTATIONAL FLUID DYNAMIC SIMULATIONS TO ASSESS HEMODYNAMICAL SIGNIFICANCE OF FIBROMUSCULAR DYSPLASIA–RELATED RENAL ARTERY STENOSIS: A FEASIBILITY STUDY**
L. Soliveri [1], M. S. Stoenoiu [2], M. Bozzetto [1], F. Meris [1], T. Robberechts [2], A. Remuzzi [1], A. Caroli [1], A. Persu [2]
[1] Bergamo (ITALY), [2] Brussels (BELGIUM)

08.55-09.05 **EFFECT OF HEART FAILURE AND ATRIAL FIBRILLATION ON CARDIORESPIRATORY FITNESS IN HEMODIALYSIS PATIENTS**
E. Pella, A. Boutou, A. Boulmpou, M. Theodorakopoulou, A. Karagiannidis, N. Haddad, F. Iatridi, I. Tsouchnikas, C. Papadopoulos, V. Vassilikos, P. Sarafidis
Thessaloniki (GREECE)

09.05-09.15 **DOES ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR EXACERBATE RENAL FUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE?**
Y. Suehiro, N. Sugano, S. Kidoguchi, T. Yokoo
Tokyo (JAPAN)

09.15-09.25 **HYPERTENSION MANAGEMENT OF CKD PATIENTS REFERRED TO HYPERTENSION EXCELLENCE CENTRES IN 27 COUNTRIES; ON BEHALF OF THE ESH HYPERTENSION AND KIDNEY WORKING GROUP**
J.-M. Halimi [1], P. Sarafidis [2], A. Persu [3], R. Kurtz [4], L. Vogt [5]
[1] Tours (FRANCE), [2] Thessaloniki (GREECE), [3] Brussels (BELGIUM), [4] Berlin (GERMANY), [5] Amsterdam (THE NETHERLANDS)

09.25-09.35 **LEFT VENTRICULAR REMODELING IN RELATION TO INTERACTION BETWEEN BLOOD PRESSURE AND SODIUM RENAL HANDLING AND INTAKE IN UNTREATED CHINESE PATIENTS**
Y.-B. Cheng, C.-M. Chan, T.-Y. Xu, Y. Li, J-G. Wang
Shanghai (CHINA)

09.35-09.45 **INCREASE IN ARTERIAL STIFFNESS IN LIVING KIDNEY DONORS AFTER RENAL DONATION**
D. Kannenkeril, M. Günes-Altan, A.Bosch, K. Striepe, K. Heller, M. Schiffer, R. Janka, K. Amann, R. E. Schmieder
Erlangen (GERMANY)

08.30-09.45 **CONVENTION HALL I D**

Pathway: Cardiovascular Renal Protection

OBESITY: A MAJOR DRIVER OF CARDIOVASCULAR RENAL DISEASE - MECHANISM AND BENEFITS OF INTERVENTIONS

Chairpersons: E. Agabiti Rosei (Brescia, ITALY), V. Kotsis (Thessaloniki, GREECE)

08.30-08.45 **Cardiovascular complications in obesity hypertension**
C. Antza (Thessaloniki, GREECE)

08.45-09.00 **Renal complications in obesity hypertension**
A. Bosch (Erlangen, GERMANY)

DEBATE
Treatment of obesity hypertension: problem solved by anti-obesity drugs?

09.00-09.15 **PRO**
F. Messerli (Bern, SWITZERLAND)

09.15-09.17 **Discussion**

09.17-09.32 **CON**
M. Volpe (Rome, ITALY)

09.32-09.34 **Discussion**

09.34-09.45 **Final discussion**

08.30-09.45 **HALL EUROPE**

Pathway: Hypertension and Clinical Practice Guidelines

ESH-ISH JOINT SESSION: BALANCING COMMON SIDE EFFECTS OF THIAZIDE/THIAZIDE-LIKE DIURETICS THROUGH ADDITION OF OTHER BLOOD PRESSURE LOWERING DRUGS

Chairpersons: F. Charchar (Ballarat, AUSTRALIA), J. Versmissen (Rotterdam, THE NETHERLANDS)

08.30-08.42 **Hyperuricemia**
M. Tomaszewski (Manchester, UNITED KINGDOM)

08.42-08.45 **Discussion**

08.45–08.57 **Hypokalemia**
B. Williams (London, UNITED KINGDOM)

08.57–09.00 **Discussion**

09.00-09.12 **Hyponatremia**
U. Wenzel (Hamburg, GERMANY)

09.12-09.15 **Discussion**

09.15-09.27 **Hyperglycemia**
B. Duly-Bouhanick (Toulose, FRANCE)

09.27-09.30 **Discussion**

09.30-09.42 **Erectile Dysfunction**
C. Vlachopoulos (Athens, GREECE)

09.42-09.45 **Discussion**

10.00-11.00 **ROOM II**

Oral Session 13

ARTIFICIAL INTELLIGENCE

Chairpersons: T. Kuznetsova (Leuven, BELGIUM),
B. Spronck (Maastricht, THE NETHERLANDS)

10.00-10.10 TIME-SERIES CLUSTERING OF RAW RECORDINGS OF 24-HOUR AMBULATORY BLOOD PRESSURE FOR RISK STRATIFICATION IN GENERAL POPULATION

E. Ntalianis, F. Sabovcik, N. Cauwenberghs, T. Kuznetsova
Leuven (BELGIUM)

10.10-10.20 PREDICTION OF CARDIOVASCULAR EVENTS IN HYPERTENSIVE SUBJECTS WITH ARTIFICIAL INTELLIGENCE TOOLS

E. Rodilla [1], O.A. Iriarte [2], B.M. Serrano [3], L.M. Ruilope [3], G. Sedano Gil [2], A.O. Arduán [3], J.A. Costa [1], O.S. Beristain [2]
[1] Valencia, [2] Esquiroz, [3] Madrid (SPAIN)

10.20-10.30 PREDICTING NEW CASES OF HYPERTENSION IN PRIMARY CARE WITH A MACHINE LEARNING TOOL

A. Norrman [1,2], J. Hasselström [1,2], G. Ljunggren [1,2], C. Wachtler [1,2], J. Eriksson [2], T. Kahan [2], P. Wändell, H. Gudjonsdottir [2], S. Lindblom [1,2], T. Ruge [3], A. Rosenblad [1,3], B. Brynedal [2], A.C Carlsson [1,2]
[1] Solna, [2] Stockholm, [3] Malmö (SWEDEN)

10.30-10.40 ACCURACY OF ARTIFICIAL INTELLIGENCE CHATBOTS' REPLIES IN GREEK VS. ENGLISH AND IN ACCORDANCE WITH THE 2023 ESH GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION

A. Ioannidis [1], D. Tsounis [2], G. Bouras [3], D. Komninou [4], A. Pechlevanis [1], E. Zalokosta [4], E. Mylona [4], C. Sidera [4], E. Markidou [4], T. Kafkia [1]
[1] Thessaloniki, [2] Nea Makri, [3] Athens, [4] Piraeus (GREECE)

10.40-10.50 DIAGNOSTIC PERFORMANCE OF SINGLE-LEAD ELECTROCARDIOGRAMS FOR ARTERIAL HYPERTENSION DIAGNOSIS: A MACHINE LEARNING APPROACH

M. Marketou, E. Angelaki, G. Barmparis, S. Maragkoudakis, K. Fragkiadakis, A. Plevritaki, E. Kampanieris, P. Kalomoirakis, S. Kassotakis, G. Kochiadakis, G. Tsironis
Heraklion (GREECE)

10.50-11.00 ASSESSMENT OF HYPERTENSIVE PATIENTS' COMPLEX METABOLIC STATUS IN THE NORTHEASTERN REGION OF HUNGARY USING DATA MINING METHODS

B. Kovacs [1], A. Nemeth [1], B. Daroczy [2], Z. Karanyi [1], L. Maroda [1], M. Zrinyi [1], A. Dioszegi [1], B. Nadro [1], T. Szabo [1], M. Harangi [1], D. Pall [1]
[1] Debrecen (HUNGARY), [2] Louvain-la-neuve (BELGIUM)

10.00-10.45 **CONVENTION HALL I C**

Mini-Symposium

supported by SERVIER

TIME TO ACT TO IMPROVE ADHERENCE IN HT MANAGEMENT: BRIDGING THE GAP BETWEEN KNOWLEDGE AND ACTION

Chairpersons: M. Burnier (Lausanne, SWITZERLAND), B. Williams (London, UNITED KINGDOM)

10.00-10.05 **Introduction**
B. Williams (London, UNITED KINGDOM)

10.05-10.17 **Challenges in HT adherence to treatment**
M. Burnier (Lausanne, SWITZERLAND)

10.17-10.20 **Patient's talk**
A. Štaraite (Vilnius, LITHUANIA)

10.20-10.32 **Innovative approaches to improve adherence: How to build a supportive eco-system**
A. Pathak (Monaco, FRANCE)

10.32-10.35 **Patient's talk**
A. Štaraite (Vilnius, LITHUANIA)

10.35-10.45 **Discussion**
M. Burnier (Lausanne, SWITZERLAND), A. Pathak (Monaco, FRANCE), A. Štaraite (Vilnius, LITHUANIA), B. Williams (London, UNITED KINGDOM)

10.00-11.00 **ROOM III**

Mini-Symposium

supported by MEDTRONIC

EXPAND YOUR HYPERTENSION TREATMENT OPTIONS: THE SYMPLICITY BLOOD PRESSURE PROCEDURE

Chairperson: A.E. Schutte (Sidney, AUSTRALIA)

10.00-10.07 **The Symplicity blood pressure procedure**
A.E. Schutte (Sidney, AUSTRALIA)

10.07-10.17 **What do the guidelines say? The safe and effective use of renal denervation**
R.E. Schmieder (Erlangen, GERMANY)

10.17-10.25 **Q&A**

10.25-10.43 **From guidelines to practice: patient selection for renal denervation**
S. Brouwers (Aalst, BELGIUM), K. Tsioufis (Athens, GREECE)

10.43-10.55 **Panel discussion: how to incorporate renal denervation into daily practice**
M. Schlaich (Perth, AUSTRALIA)

10.55-11.00 **Conclusion**
A.E. Schutte (Sidney, AUSTRALIA)

10.00-11.15 **CONVENTION HALL I D**

Pathway: Cardiovascular Renal Protection

ESC-HFA JOINT SESSION: HYPERTENSION AND HEART FAILURE MANAGEMENT UPDATE

Chairpersons: E. Agabiti Rosei (Brescia, ITALY), M. Camafort (Barcelona, SPAIN)

10.00-10.12 **Hypertension in HFpEF - pathophysiology**
M. Böhm (Homburg, GERMANY)

10.12-10.15 **Discussion**

10.15-10.27 **Management of HTN in HFpEF**
D. Konstantinidis (Athens, GREECE)

10.27-10.30 **Discussion**

10.30-10.42 **Atrial fibrillation and HFpEF**
K. Tsioufis (Athens, GREECE)

10.42-10.45 **Discussion**

10.45-10.57 **The obese HFpEF phenotype: a treatable disease**
S. Masi (Pisa, ITALY)

10.57-11.00 **Discussion**

11.00-11.15 **Q&A**

10.00-11.15 **HALL EUROPE**

Pathway: Hypertension and Clinical Practice Guidelines

BLOOD PRESSURE MEASUREMENT CHALLENGES IN CLINICAL PRACTICE

Chairpersons: R. Cífková (Prague, CZECH REPUBLIC), A. de la Sierra (Terrassa, SPAIN), P. Palatini (Vittorio Veneto, ITALY)

PART I: Obesity and atrial fibrillation

10.00-10.15 **How to measure BP in subjects with large arms**
F. Saladini (Cittadella, ITALY)

10.15-10.30 **BP measurement in patients with atrial fibrillation**
G.S. Stergiou (Athens, GREECE)

PART II: Orthostatic hypertension, a newcomer among the hypertension phenotypes

10.30-10.45 **How to measure BP in the standing position: for whom and how?**
A. Kollias (Athens, GREECE)

10.45-11.00 **Identification and management of patients with orthostatic hypertension**
J. Jordan (Cologne, GERMANY)

11.00-11.15 **Q&A**

11.30-13.00 **EXHIBITION AREA**

Moderated E-poster Session 2

TOTEM T01 Epidemiology
TOTEM T02 and T03 Blood Pressure Measurement
TOTEM T04 Kidney
TOTEM T05 and T06 Heart, Brain, Vascculature
TOTEM T07 Risk factors
TOTEM T08 Clinical Studies
TOTEM T09 Secondary HTN and Diagnostic procedures
TOTEM T10 Children, Adolescents, Women
TOTEM T11 Diabetes, Obestiy, Comorbidities
TOTEM T12 Device Based Therapy, Resistant Hypertension, Adherence
TOTEM T13 Hypertension Phenotypes, Older Persons
TOTEM T14 Pharmacotherapy and Lifestyle interventions
TOTEM T15 Pathophysiology, Genomics
TOTEM T16 General hypertension research

13.00-13.45 **ROOM III**

ESH General Assembly

13.15-14.15 **CONVENTION HALL I C**

Satellite symposium

organised by Sciarc, kindly supported by BAYER

ACHIEVING EXCELLENCE IN THE TREATMENT OF HEART AND KIDNEY DISEASE WITH NON-STEROIDAL MRAS

Chairpersons: R.E. Schmieder (Erlangen, GERMANY),
H. Heerspink (Groningen, THE NETHERLANDS)

13.15-13.20 **Welcome & Introduction**
Introduction: H. Heerspink (Groningen, THE NETHERLANDS)

13.20-13.35 **Removing barriers to treatment of CKD - key characteristics of non-steroidal MRAs**
P. Fioretto (Padua, ITALY)

13.35-13.50 **Improving cardiovascular and kidney outcomes with Finerenone in Type 2 Diabetes**
P. Sarafidis (Thessaloniki, GREECE)

13.50-14.05 **The role for non-steroidal MRAs in CKD and heart failure: Practical considerations and future perspectives**
S. Anker (Berlin, GERMANY)

14.05-14.15 **Discussion and conclusions**
R.E. Schmieder (Erlangen, GERMANY)

14.15-15.15 **ROOM III**

Oral Session 14

LATE BREAKERS 1

Chairpersons: A.M. Heagerty (Manchester, UNITED KINGDOM),
B. Ponte (Genève, SWITZERLAND)

14.15-14.25 **STOPPING ANTIHYPERTENSIVE TREATMENT AMONG HYPERTENSIVE PATIENTS IN PRIMARY CARE: THE STOP-TRIAL**
J.-M.Boivin [1], J. Ferreira [1,2,3], K. Duarte [3], Z. Lamiral [3], P. Rossignol [1,2,4], N. Girerd [1,2], M. Lopez-Sublet [1]
[1] Nancy, [2] Vandoeuvre Les Nancy (FRANCE), [3] Porto (PORTUGAL), [4] Monaco (MONACO)

14.25-14.35 **EFFECT OF RENAL DENERVATION ON BLOOD PRESSURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND UNCONTROLLED HYPERTENSION: RESULTS OF A PROSPECTIVE RANDOMIZED SHAM-CONTROLLED STUDY**
R.E. Schmieder [1], D. Kannenkeril [1], M. Böhm [2], F. Mahfoud [2], L. C. Rump [3], J. Stegbauer [3], M. Van Der Giet [4], M. Schiffer [1], R. Veelken [5], M. Uder [1], A. Schmid [1]
[1] Erlangen, [2] Homburg, [3] Düsseldorf, [4] Berlin, [5] Nuremberg (GERMANY)

14.35-14.45 **ASSOCIATION OF CLINIC AND AMBULATORY BLOOD PRESSURE WITH MORTALITY IN PATIENTS WITH AND WITHOUT DIABETES**
L. Lauder [1], M. Böhm [1], A. De La Sierra [2], F. Mahfoud [1], I. Schwantke [1], B. Haring [1], E. Vinyoles [2], M. Gorostidi [3], J. Segura [4], B. Williams [5], N. Staplin [5], L. M. Ruilope [2]
[1] Homburg (GERMANY), [2] Barcelona, [3] Oviedo, [4] Madrid (SPAIN), [5] London (UNITED KINGDOM)

14.45-14.55 **EFFICACY AND SAFETY OF SACUBITRIL/ALLISARTAN FOR THE TREATMENT OF PRIMARY HYPERTENSION: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY**
W. Zhang, J. Zhang, J. Yan, Q. Ge, X. Lu, S. Chen, W. Xu, J. Sun, J. Li, Z. Liu, Q. Wang, X. Zhou, Y. Li, J. Wang
Shanghai (CHINA)

14.55-15.05 **HIGHER INCIDENCE OF CARDIOVASCULAR EVENTS IN A LARGE REAL-WORLD DATABASE IN THE TRIENNIUM 2020-2022 COMPARED TO A PRE-COVID TRIENNIUM IS INDEPENDENT OF CARDIOVASCULAR RISK FACTORS**

A. Battistoni [1], G. Gallo [1], C. Morisco [2], G. Piccinocchi [2], R. Piccinocchi [2], M. Fini [1], S. Proietti [1], S. Bonassi [1], B. Trimarco [2], M. Volpe [1]
[1] Rome, [2] Naples (ITALY)

15.05-15.15 **MANAGEMENT OF HYPERTENSION IN THE EARLY POSTPARTUM: A RANDOMIZED CONTROLLED TRIAL**

L. Bortolotto [1], R. Marques [2], S. Maia [2], A. Araujo [2]
[1] Sao Paulo (BRAZIL), [2] Joao Pessoa (BRAZIL)

14.15-15.30 **ROOM II**

Symposium

supported by MERCK

COMBINATION OF A BETA-BLOCKER WITH CALCIUM CHANNEL BLOCKER IN HYPERTENSION: KNOWLEDGE IN PRACTICE

Chairpersons: R. Kreutz (Berlin, GERMANY), G. Parati (Milan, ITALY)

14.15–14.40 **BB-CCB combinations in cardiometabolic conditions: what is the pharmacological evidence?**
A. Pathak (Monaco, FRANCE)

14.40–15.05 **BB-CCB combinations in hypertension: maximizing the benefits**
F. Mahfoud (Hamburg, GERMANY)

15.05–15.25 **BB-CCB combinations in hypertension and CAD: setting up the goals**
J. Lopez-Sendon (Madrid, SPAIN)

15.25–15.30 **Conclusions**

14.15-15.15 **CONVENTION HALL I D**

Pathway: Cardiovascular Renal Protection

ALDOSTERONE: A MAJOR CULPRIT OF CARDIOVASCULAR-RENAL DAMAGE

Chairpersons: L. Amar (Paris, FRANCE), A. Prejbisz (Warsaw, POLAND)

14.15-14.30 **Aldosterone blockade in Cardio-Renal disease - a must?**
M. van der Giet (Berlin, GERMANY)

14.30-14.45 **MRA vs. ASI vs. Modulators**
M. Azizi (Paris, FRANCE)

14.45-15.00 **New molecular markers and therapeutic perspectives**
P. Mulatero (Turin, ITALY)

15.00-15.15 **Q&A**

14.15-15.15 **HALL EUROPE**

Pathway: Hypertension and Clinical Practice Guidelines

HOW TO PRESCRIBE LIFESTYLE INTERVENTIONS

Chairpersons: S. Brouwers (Aalst, BELGIUM)
J. Polonia (Matosinhos, PORTUGAL)

14.15-14.30 **Physical activity**
V. Cornelissen (Leuven, BELGIUM)

14.30-14.45 **Healthy diet**
F. Charchar (Ballarat, AUSTRALIA)

14.45-15.00 **Supportive tools**
F. Limbourg (Hannover, GERMANY)

15.00-15.15 **Q&A**

14.30-15.30 **CONVENTION HALL I C**

Mini-Symposium

Organised by Science Collected kindly supported by AstraZeneca

ONE HEART AND TWO KIDNEYS: PROMOTING ORGAN PROTECTION USING SGLT2 INHIBITORS IN PATIENTS WITH CKD AND HYPERTENSION

Chairperson: M. Böhm (Homburg, GERMANY)
Presenters: F. Mallamaci (Reggio Calabria, ITALY), G.S. Stergiou (Athens, GREECE)

14.30-14.35 **Welcome and introduction**
M. Böhm (Homburg, GERMANY)

14.35-14.45 **Chapter 1 - Where are we now?**
M. Böhm (Homburg, GERMANY)

14.45–15.15 **Chapter 2 – Evolving standard of care: SGLT2 inhibitors for patients with CKD and hypertension**
M. Böhm (Homburg, GERMANY), F. Mallamaci (Reggio Calabria, ITALY), G.S. Stergiou (Athens, GREECE)

Panel discussion

15.15–15.25 **Chapter 3 – Hearing from you! Q&A**

15.25-15.30 **The final chapter...**
M. Böhm (Homburg, GERMANY)

15.45-17.00 **CONVENTION HALL II**

Plenary Session 2

PRESENTATION OF ESH AWARDS

Moderator: T. Weber (Wels, AUSTRIA)

Chairpersons: G. Grassi (Milan, ITALY), R. Kreutz (Berlin GERMANY), T. Weber (Wels, AUSTRIA)

15.45 **Welcome by ESH President**
G. Grassi (Milan, ITALY)

15.45–15.50 **Björn Folkow Award and Lecture**
Awardee: J. Danser (Rotterdam, THE NETHERLANDS)

15.50–16.10 **Alberto Zanchetti Life Achievement Award**
Awardee: R. Cífková (Prague, CZECH REPUBLIC)

16.10–16.20 **ESH Honorary Membership**
Awardee: M. Viigimaa (Tallinn, ESTONIA)

16.20–16.30 **Paul Milliez Award**
Awardee: M. Burnier (Lausanne, SWITZERLAND)

16.30–16.40 **2024 SOMNOmedics Young Investigators Award**
Awardee: K. Kyriakoulis (Athens, Greece)

16.40–16.50 **Best Oral and Best Poster Presentation Awards**

16.50–17.00 **Björn Folkow Lecture: “Antihypertensive treatment: are we ready for the future?”**
J. Danser (Rotterdam, THE NETHERLANDS)

17.30-18.45 **CONVENTION HALL I C**

Oral Session 15

PHARMACOTHERAPY – LIFESTYLE

Chairpersons: A.J. Danser (Rotterdam, THE NETHERLANDS),
M.S. Fernandez Alfonso (Madrid, SPAIN)

17.30-17.45 **MINI-LECTURE**
Importance and potential of endothelin receptor antagonists for the treatment of hypertension
M. Schlaich (Perth, AUSTRALIA)

17.45-17.55 **HYPERTENSIVE EMERGENCIES AND URGENCIES: ADHERENCE TO GUIDELIENS AND RELATIONSHIP BETWEEN BLOOD PRESSURE MANAGEMENT AND IN-HOSPITAL MORTALITY**
A. Maloberti [1], T. Valobra [2], V. Giani [1], I. Garofani [1], L. De Censi [1], M. Galasso [1], V. Colombo [1], A. Menna [1], G. Annalisa [1], C. Ferretti [1], A.Sultana [1], S. Gheda [1], N. Capsoni [1], F. Galbiati [1], M. Bombelli [1,2], C. Giannattasio [1]
[1] Milan, [2] Desio (ITALY)

17.55-18.05 **FEASIBILITY STUDY TO ASSESS THE DELIVERY OF A NOVEL ISOMETRIC EXERCISE INTERVENTION FOR PEOPLE WITH STAGE 1 HYPERTENSION**
C. Farmer, M. Rees-Roberts, E. Santer, J. O'Driscoll, D. Macinnes, V. Short, T. Pellatt-Higgins, A. Mills, K. Gousia, A. West, J. Darby, R. Borthwick, T. Doulton, P. Swift, J. Wiles
Canterbury (UNITED KINGDOM)

18.05-18.15 **COUNTERACTING ANGIOTENSINOGEN SMALL INTERFERING RNA-MEDIATED ANTIHYPERTENSIVE EFFECTS WITH REVERSIR**
E. Cruz López [1], D. Ye [1], R. Van Veghel [1], I.M. Garrelds [1], A. Kasper [2], K. Wassarman [2], H.-C. Tu [2], I. Zlatev [2], A.H.J. Danser [1]
[1] Rotterdam (THE NETHERLANDS), [2] Cambridge (USA)

18.15-18.25 **POTASSIUM-ENRICHED SALT EFFECTIVELY REDUCES SODIUM INTAKE IN THE NURSING HOME POPULATION OF NORTHERN CHINA: THE CHINA SALT TRIAL**
X. Meng [1], X. Dou [1], H. Wei [1], W. Li [2], J. Zhao [3], S. Zhao [4], Y. Liu [1], H. Zhang [1], L. Liu [1]
[1] Beijing, [2] Leting, [3] Wendeng, [4] Shouyang (CHINA)

18.25-18.35 **PRACTICE-BASED BLOOD PRESSURE MANAGEMENT IN 1000 PATIENTS USING THE CUREAPP HT DIGITAL THERAPEUTICS FOR HYPERTENSION**
A. Nomura [1], Y. Takagi [2], T. Tanigawa [2], K. Kario [3]
[1] Kanazawa, [2] Tokyo, [3] Tochigi (JAPAN)

18.35-18.45 **THE EFFECT OF DARK AND WHITE CHOCOLATE ON BLOOD PRESSURE AND RENAL PERFUSION AS ASSESSED WITH DOPPLER ULTRASOUND IN HEALTHY VOLUNTEERS**
M. Pruijm, L. Gargiulo, W. Brito, M. Hendriks-Balk, K. Theiler, G. Wuerzner
Lausanne (SWITZERLAND)

17.30-18.45 **ROOM III**

Oral Session 16

VASCULATURE

Chairpersons: M. Dorobantu (Bucharest, ROMANIA),
U. Wenzel (Hamburg, GERMANY)

17.30-17.40 **CLINICAL CHARACTERISTICS OF PATIENTS WITH FIBROMUSCULAR DYSPLASIA WITH AND WITHOUT SPONTANEOUS CERVICAL ARTERY DISSECTION IN THE ARCADIA-POL STUDY**
I. Sterlinski [1], P. Talarowska [1], S. Kolodziejczyk-Kruk [1], E. Szwench-Pietrasz [1], E. Florczak [1], J. Kadziela [1], I. Michalowska [1], A. Michalowska [1], A. Januszewicz [1], A. Persu [2], M. Januszewicz [1]
[1] Warsaw (POLAND), [2] Brussels (BELGIUM)

17.40-17.50 **DEFINITION, VALIDATION AND CALIBRATION OF AN OUTCOME-DRIVEN THRESHOLD FOR PULSE PRESSURE AMPLIFICATION**
Q.-F. Huang [1], A. De -Wei [1,2,3], L. Aparicio [4], Y.-B. Cheng [1], Y. Li [1], J. Staessen [1,2,3]
[1] Shanghai (CHINA), [2] Mechelen, [3] Leuven (BELGIUM), [4] Buenos Aires (ARGENTINA)

17.50-18.00 **PREDICTIVITY OF ESTIMATED PULSE WAVE VELOCITY FOR FATAL AND NONFATAL OUTCOMES IN RURAL POPULATION**
M. Domislovic [1], M. Abramovic Baric [2], V.Matijevic [3], Z. Bosnic [4], I. Brzic [2], K. Capak [1], V. Prelevic [5], D. Radunovic [5], A. Jelakovic [1,6], J. Josipovic [1], B.Jelakovic [1]
[1] Zagreb, [2] Bebrina, [3] Slavonski Kobas, [4] Slavonski Brod (CROATIA), [5] Podgorica (MONTENEGRO), [6] Rijeka (CROATIA)

18.00-18.10 **ASSOCIATION OF LONG-TERM TIME IN TARGET RANGE FOR SYSTOLIC BLOOD PRESSURE SINCE CHILDHOOD WITH ARTERIAL STIFFNESS IN MIDLIFE: A 36-YEAR PROSPECTIVE COHORT STUDY**
Y. Wang [1], H. Qi [2], H. Jia [1], D. Wang [1], Y. Sun [1], M.-F. Du [1], G.-L. Hu [1], Z.-Y. Man [1], C. Chu [1], J. Chang [3], C. Delles [4], L. Zhang [2], J.-J. Mu [1]
[1] Xi An, [2] Beijing (CHINA), [3] New Haven (USA), [4] Glasgow (UNITED KINGDOM)

18.10-18.20 **THE RELATION OF CIRCULATING VASCULAR BIOMARKERS TO ENDOTHELIAL FUNCTION AND SKIN MICROVASCULAR REACTIVITY IN PATIENTS WITH HYPERTENSION AND DECLINING KIDNEY FUNCTION**
A. Jekell, K. Lundwall, T. Kahan
Stockholm (SWEDEN)

18.20-18.30 **CAROTID-FEMORAL PULSE WAVE VELOCITY PROGRESSION IN HYPERTENSIVE PATIENTS IS ASSOCIATED WITH SUBSEQUENT CV OUTCOMES**
A. Maloberti [1], P. Rebora [1], G. Occhino [1], A. Andreano [1], R.C.My Intravaia [1], C. Tognola [1], G. Toscani [1], M. Morelli [1], S. Pezzoli [1], L. Cavalieri D'Oro [2], A. Russo [1], C. Giannattasio [1]
[1] Milan, [2] Monza (ITALY)

18.30-18.45 **MINI-LECTURE**
Vascular aging: how to assess
R.M. Bruno (Paris, FRANCE)

17.30-18.45 **ROOM II**

Clinical Cases II

Chairpersons: E. Agabiti Rosei (Brescia, ITALY), M. Doumas (Thessaloniki, GREECE)

17.35-18.10 **A young athlete with hypertension and hypokalaemia**
A.-G. Lopez, D. Guerrot (Rouen, FRANCE)

18.10-18.45 **Navigating Hypertension in Hypertrophic Obstructive Cardiomyopathy: A Cardiovascular Conundrum**
S.W. Dooley, J. Cluett (Boston, USA)

17.30-18.45 **CONVENTION HALL I D**

Pathway: Cardiovascular Renal Protection

FIBROMUSCULAR DYSPLASIA: CASE BASED DISCUSSION

Chairpersons: A. Persu (Brussels, BELGIUM), A. Januszewicz (Warsaw, POLAND)

Panelists: B. Ponte (Genève, SWITZERLAND), F. Limbourg (Hannover, GERMANY)

17.30-17.40 **Case 1: Classic presentation of FMD**
T. Robberechts (Jette, BELGIUM)

17.40-17.48 **Discussion**

17.48-17.58 **Case 2: Which vascular beds are affected by FMD**
I. Achek (Geneve, SWITZERLAND)

17.58-18.06 **Discussion**

18.06-18.16 **Case 3: FMD and SCAD: overlapping entities**
A. Damianaki (Lausanne, SWITZERLAND)

18.16-18.24 **Discussion**

18.24-18.34 **Case 4: FMD in polycystic kidney disease - treatment options**
D. Kannenkeril (Erlangen, GERMANY)

18.34-18.42 **Discussion**

18.42-18.45 **Final discussion**

17.30-18.45 **HALL EUROPE**

Pathway: Hypertension and Clinical Practice Guidelines

HYPERTENSIVE PATIENTS: OPPORTUNITIES AND CHALLENGES

In collaboration with the European Society of Geriatric Medicine (EuGMS)

Chairpersons: A. Benetos (Nancy, FRANCE), A. Coca (Barcelona, SPAIN), A. Ekdahl (Helsingborg, SWEDEN), C. Polidori (Cologne, GERMANY)

PART I

17.30-17.40 **Patient profiles and factors to consider when thinking about deprescribing antihypertensive treatment in clinical practice**
J. Sheppard (Oxford, UNITED KINGDOM)

17.40-17.50 **Frailty assessment of the older patient with hypertension: Basic geriatrics for all?**
M. Kotsani (Nice, FRANCE)

17.50-18.00 **Q&A**

PART II – DEBATE
Deprescribing of antihypertensive drugs: an essential tool in the care of older hypertensives

18.00-18.13 **PRO**
A. Benetos (Nancy, FRANCE)

18.13-18.15 **Discussion**

18.15-18.28 **CON**
C. Thomopoulos (Athens, GREECE)

18.28-18.30 **Discussion**

18.30-18.45 **Conclusion**

33rd EUROPEAN MEETING ON HYPERTENSION AND CARDIOVASCULAR PROTECTION

SCIENTIFIC PROGRAMME

MONDAY, JUNE 3

08.30-09.30 **CONVENTION HALL I D**

Pathway: Cardiovascular Renal Protection

Oral Session 17

LATE BREAKERS 2

Chairpersons: A.F. Dominiczak (Glasgow, UNITED KINGDOM), G. Wuerzner (Lausanne, SWITZERLAND)

08.30-08.40 EFFECT OF DASH VS. MEDITERRANEAN DIET ON METABOLIC SYNDROME PREVALENCE IN ADULTS WITH HIGH NORMAL BLOOD PRESSURE OR GRADE 1 HYPERTENSION: A RANDOMIZED CONTROLLED TRIAL
C. Filippou, C. Thomopoulos, D. Konstantinidis, K. Dimitriadis, F. Tatakis, E. Siafi, E. Manta, S. Drogkaris, M. Stathoulopoulou, D. Polyzos, K. Grigoriou, N. Kakouri, I. Tsoumpou, I. Andrikou, A. Kasiakogias, K. Tsioufis
Athens (GREECE)

08.40-08.50 PEAK NOCTURNAL HOME BLOOD PRESSURE AS AN EARLY AND STRONG NOVEL RISK FACTOR FOR STROKE: THE PRACTITIONER-BASED NATIONWIDE J-HOP NOCTURNAL BP STUDY
K. Kario [1], Y. Okawara [1], H. Kanegae [2], N. Tomitani [1], S. Hoshide [1]
[1] Shimotsuke, [2] Tokyo (JAPAN)

08.50-09.00 HOME BLOOD PRESSURE DURING NIGHT-TIME SLEEP AS A BETTER TREATMENT TARGET FOR PATIENTS WITH HYPERTENSOIN: A PROOF-OF-CONCEPT RANDOMIZED CONTROLLED TRIAL
E. Kam-Pui Lee [1], B. Hk Yip [1], B. Yan [1], S. Wong [1], W.-H. Chung [1], K.-F. Chow [1], J.-H. Han [1], S.-Y. Leung [1], S. Choi [1], E. Yu [1], A. Mihailidou [2], R. Mcmanus [3]
[1] Hong Kong (HONG KONG), [2] Sydney (AUSTRALIA), [3] Oxford (UNITED KINGDOM)

09.00-09.10 ANTIHYPERTENSIVE TREATMENT OF MASKED HYPERTENSION GUIDED BY AMBULATORY BLOOD PRESSURE MONITORING: A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
J.-F. Huang [1], D. Y. Zhang [1], D.-W. An [1], M.-X. Li [1], C.-Y. Liu [1], Y.-Q. Feng [2], Q.-D.Zheng [3], X. Chen [1], J. Staessen [4], J.-G. Wang [1], Y. Li [1]
[1] Shanghai, [2] Guangzhou, [3] Taizhou (CHINA), [4] Mechelen (BELGIUM)

09.10-09.20 THE MEDICAL IMPACT OF EMERGENT BANNING OF N-NITROSODIMETHYLAMINE (NDMA)- CONTAMINATED ANTIHYPERTENSIVE DRUG: A NATIONWIDE LONGITUDINAL COHORT STUDY
H.-Y. Lee [1], M.-C. Cho [2]
[1] Seoul, [2] Cheong Ju (SOUTH KOREA)

09.20-09.30 EFFECT OF SEQUENTIAL NEPHRON BLOCKADE X DUAL RENIN-ANGIOTENSIN SYSTEM BLOCKADE +BISOPROLOL IN THE TREATMENT OF RESISTANT HYPERTENSION, A RANDOMIZED CONTROLLED TRIAL (RESHYPOT)
E. Do Esp Cestari [1], J. Fernando Vilela-Martin [2], L. Neves Cosenso-Martin [2], T. Azevedo Rubio [3], J. Rodrigue Roma Uyemura [2], V. Da Silva Lopes [2], L. Aparecid Barufi Fernandes [1], L.H. Bonalume Tacito [2], H. Moreno Junior [3], J.C. Yugar-Toledo [2]
[1] Votuporanga, [2] São José Do Rio Preto, [3] Campinas (BRAZIL)

08.30-09.30 **ROOM III**

Oral Session 18

EPIDEMIOLOGY 2

Chairpersons: A. Coca (Barcelona, SPAIN), V. Cornelissen (Leuven, BELGIUM)

08.30-08.40 TYG INDEX AS PREDICTOR OF METABOLIC SYNDROME IN YOUNG TO-MIDDLE AGE STAGE I HYPERTENSIVES, UNTREATED AT THE BASELINE
F. Saladini [1], L. Mos [2], O. Vriz [2], G. Garavelli [3], A. Mazzer [4], M. Rattazzi [4], P. Palatini [1]
[1] Padua, [2] Udine, [3] Cremona, [4] Treviso (ITALY)

08.40-08.50 CHRONIC KIDNEY DISEASE INCIDENCE AND CARDIORESPIRATORY FITNESS ASSOCIATION IN HYPERTENSIVE PATIENTS
P. Kokkinos [1], A. Pittaras [2], C. Faselis [2], I. Samuel [2], S. Patel [2], M. Doumas [3], J. Gollie [2], H. Grassos [2], J. Myers [4]
[1] New Brunswick, DC (USA), [2] Washington DC (USA), [3] Thessaloniki (GREECE), [4] Palo Alto, Stanford (USA)

08.50-09.00 ANTIHYPERTENSIVE DRUG THERAPY AND RISK OF DEMENTIA: REAL-WORLD EVIDENCE FROM A LARGE OLD POPULATION
F. Rea, G. Corrao, G. Mancia
Milan (ITALY)

09.00-09.10 CUMULATIVE DIASTOLIC BLOOD PRESSURE BURDEN IN NORMAL SYSTOLIC BLOOD PRESSURE AND CARDIOVASCULAR DISEASE
S.M.J. Cho [1], H. Lee [2], S. Koyama [1], A. Schuermans [3], S. Ganesh [1], W. Hornsby [1], M. I Honigberg [1], P. Natarajan [1]
[1] Boston (USA), [2] Seoul (SOUTH KOREA), [3] Leuven (BELGIUM)

09.10-09.20 HYPERTENSION, UNCONTROLLED HYPERTENSION AND RESISTANT HYPERTENSION: PREVALENCE, COMORBIDITIES AND PRESCRIBED MEDICATIONS IN 228,406 ADULTS RESIDENT IN URBAN AREAS. A POPULATION-BAS
A. Sartorio, S. Romano, G. Rigon, M. Albrigi, G. Tebaldi, L. Cristin, G. Burrei, C. Fava, P. Minuz
Verona (ITALY)

09.20-09.30 VASCULAR AGEING MANIFESTATIONS AND RISK OF HYPERTENSION IN THE COMMUNITY. A CLUSTERING ANALYSIS OF CAROTID ECHO-TRACKING DATA ON 10,157 PARTICIPANTS
G.A. Alanis [1], P. Boutouyrie [1], R.M. Bruno [1], M. Abouqateb [1], R. Climie [2], T. Van Sloten [3], N. Danchin [1], S. Laurent [1], X. Jouven [1], J.-P. Empana [1]
[1] Paris (FRANCE), [2] Hobart (AUSTRALIA), [3] Utrecht (THE NETHERLANDS)

08.30-09.30 **ROOM II**

Clinical Cases III

Chairpersons: J. Brguljan (Ljubljana, SLOVENIA),
L. Bronze (Lisbon, PORUGAL)

08.30-08.50 **Local release of renin unveils intrarenal fibromuscular dysplasia**
P. Minuz (Verona, ITALY)

08.50-09.10 **Hypertension and arterial stiffness in a patient with Takayasu arteritis: cause or effect?**
A. Georgiou (Thessaloniki, GREECE)

09.10-09.30 **When radiation strikes back**
T. Burkard (Basel, SWITZERLAND)

08.30-09.30 **CONVENTION HALL I C**

Hypertension emergencies: malignant hypertension - A systemic cardiovascular disease

Chairperson: F. Messerli (Bern, SWITZERLAND)

Panelists: P. Cunha (Guimaraes, PORTUGAL),
M. Doumas (Thessaloniki, GREECE)

08.30-08.45 **An increasing unrecognized problem**
A. Januszewicz (Warsaw, POLAND)

08.45-09.00 **A vicious circle of cardiovascular, cerebral and kidney complications**
B.-J. Van Den Born (Amsterdam, THE NETHERLANDS)

09.00-09.15 **Blood pressure lowering strategies**
M.L. Muiesan (Brescia, ITALY)

09.15-09.30 **Q&A**

08.30-09.30 **HALL EUROPE**

Pathway: Hypertension and Clinical Practice Guidelines

TEAM-BASED CARE OPPORTUNITIES

Chairpersons: M.S. Fernandez Alfonso (Madrid, SPAIN), P.A. Modesti (Florence, ITALY)

08.30-08.42 **Pharmacists**
E. Rodilla Sala (Valencia, SPAIN)

08.42-08.45 **Discussion**

08.45-08.57 **Nurses**
J. Blacher (Paris, FRANCE)

08.57-09.00 **Discussion**

09.00-09.12 **Telemedicine**
S. Omboni (Varese, ITALY)

09.12-09.15 **Discussion**

09.15-09.27 **Patients**
F. Limbourg (Hannover, GERMANY)

09.27-09.30 **Discussion**

10.00-11.00 **CONVENTION HALL I C**

Oral Session 19

ESH EXCELLENCE CENTRE RESEARCH

Chairpersons: C. Delles (Glasgow, UNITED KINGDOM), T. Weber (Wels, AUSTRIA)

10.00-10.05 **INTRODUCTION**
C. Delles (Glasgow, UNITED KINGDOM), T. Weber (Wels, AUSTRIA)

10.05-10.15 **CHEMICAL ADHERENCE IN RESISTANT HYPERTENSION: PILOT STUDY IN AN ESH EXCELLENCE CENTER**
B. Sautenet, J.M. Halimi, H. Longuet, J. Gueguen, P. Gatault, N. Rabot, M. François, M. Buchler, H. Auclair, F. Debacq, F. Darrouzain, T. Bejan-Angoulvant
Tours (FRANCE)

10.15-10.25 **THE IMPACT OF THE COVID-19 PANDEMIC ON OFFICE AND 24-HOUR BLOOD PRESSURE PHENOTYPES (ESH ABPM COVID-19 STUDY)**
A. Ostrowska [1], W. Wojciechowska [1], M. Rajzer [1], K. Reinhold [2], T. Weber [3], M. Bursztyn [4], A. Persu [5], G.S. Stergiou [6], G. Kielbasa [1], G. Parati [7], G. Bilo [7], G. Grassi [8], G. Mancia [7], A. Januszewicz [9]
[1] Krakow (POLAND), [2] Berlin (GERMANY), [3] Wels (AUSTRIA), [4] Jerusalem (ISRAEL), [5] Brussels (BELGIUM), [6] Athens (GREECE), [7] Milan, [8] Monza (ITALY), [9] Warsaw (POLAND)

10.25-10.35 **CORRELATION OF BLOOD PRESSURE AND CLINICAL PRESENTATION WITH ARTERIAL PHENOTYPE IN RENAL FIBROMUSCULAR DYSPLASIA: TOWARDS A NEW CLASSIFICATION OF LESIONS IN THE FEIRI COHORT**
T. Robberechts [1], P. Delmotte [1], M. Lopez-Sublet [1], L.S. Aparicio [2], D. Gordin [3], Z. Dika [4], D.J. Van Twist [5], S. Savard [1], K. Zen [1], C. Canning [1], P. De Leeuw [6], P. Minuz [7], A. Januszewicz [8], P. Van Der Niepen [1], M.S. Stoenoiu [1], A. Persu [1]
[1] Brussels (BELGIUM), [2] Buenos Aires (ARGENTINA), [3] Helsinki (FINLAND), [4] Zagreb (CROATIA), [5] Sittard, [6] Maastricht (THE NETHERLANDS), [7] Verona (ITALY), [8] Warsaw (POLAND)

10.35-10.45 **ASSESSMENT AND MANAGEMENT OF PATIENTS WITH OBESITY AND HYPERTENSION IN EUROPEAN SOCIETY OF HYPERTENSION EXCELLENCE CENTRES. A SURVEY FROM THE ESH WORKING GROUP ON DIABETES AND META**

C. Antza [1], G. Grassi [2], T. Weber [3], A. Persu [4], J. Jordan [5], P. Nilsson [6], J. Redon [7], S. Stabouli [1], R. Kreutz [8], V. Kotsis [1]
[1] Thessaloniki (GREECE), [2] Milan (ITALY), [3] Wels (AUSTRIA), [4] Brussels (BELGIUM), [5] Cologne (GERMANY), [6] Malmo (SWEDEN), [7] Madrid (SPAIN), [8] Berlin (GERMANY)

10.45-10.55 **A EUROPEAN SURVEY TO IDENTIFY CURRENT PRACTICES ON THE TREATMENT OF HYPERTENSION IN ADULTS >75 YEARS IN ESH EXCELLENCE CENTRES**

M. Camafort, G. Bahat, J. Bogaert, D.E. Dallmeier Rojas, T. De Backer, G. Desideri, R. Kenny, A. Protogerou, M. Rajzer, H. Ribeiro, J. Sheppard, A. Ungar, A. Virdis, C. Labat, T. Weber, A. Persu, A. Benetos
Milan (ITALY)

10.55-11.00 **Future perspectives**
C. Delles (Glasgow, UNITED KINGDOM),
T. Weber (Wels, AUSTRIA)

10.00-11.00 **ROOM II**

Oral Session 20

PATHOPHYSIOLOGY

Chairpersons: M. Schlaich (Perth, AUSTRALIA),
R. Veelken (Erlangen, GERMANY)

10.00-10.10 **CHARACTERIZATION OF EARLY FUNCTIONAL, STRUCTURAL AND MOLECULAR ALTERATIONS IN A RAT MODEL OF CARDIORENAL SYNDROME TYPE IV: ROLE OF BMP-2**

M. Sanz-Gómez [1], S. Vázquez-Sánchez [1], F.J. Manzano-lista [1], P. Palma-Guzmán [1], A.K. Guzmán-Aguayo [1], E. Bragado-García [1], R. Kreutz [2], G. Ruiz-Hurtado [1], M.S. Fernández-Alfonso [1]
[1] Madrid (SPAIN), [2] Berlin (GERMANY)

10.10-10.20 **PDGFRALPHA ACTIVATION LEADS TO BLOOD PRESSURE INCREASE AND SMALL ARTERIES MEDIAL HYPERTROPHY IN MALE MICE**

F. Atassi [1], A. Frisdal [1], E. Roy-Vessieres [2], C. Proux [2], J. Solinc [1], E.Trenquier [1], N. Suffee [1], G. Dilanian [1], E. Balse [1], D. Henrion [2], S. Nadaud [1]
[1] Paris, [2] Angers (FRANCE)

10.20-10.30 **PLASMA EXOSOMES FROM HYPERTENSIVE PATIENTS WITH RENAL DYSFUNCTION ARE ENRICHED IN SPECIFIC REDOXIMIRS AND FIBROMIRS**

J. Redon, O. Martinez-Arroyo, A. Flores-Chova, M. Mendez Debacts, S. Martinez-Hervas, M.J Forner, A. Ortega, R. Cortes
Valencia (SPAIN)

10.30-10.40 **DEFICIENCY OF THE COMPLEMENT RECEPTOR C5AR2 HAS NO EFFECT ON BLOOD PRESSURE AND END ORGAN DAMAGE IN ANGIOTENSIN II INDUCED HYPERTENSION**

L. Dreher [1], M. Bode [1], N. Ehnert [1], G.R. Herrnstadt [1], C. Meyer-Schwesinger [1], J. Köhl [2], T.B. Huber [1], U.O. Wenzel [1]
[1] Hamburg, [2] Lübeck (GERMANY)

10.40-10.50 SIGNIFICANCE OF THE NAV 1.8. VOLTAGE-GATED, TETRODOTOXIN-RESISTANT SODIUM CHANNEL FOR THE RENAL SENSORY INNERVATION IN MICE AND RATS
K. Rodionova [1], T. Ditting [1,2], K. Holzmann[1], F. Bach[1], N. Cordasic[1], K.-F. Hilgers [1], P. Linz[1], M. Schiffer[1], K. Amann [1], R. Veelken [1,2]
[1] Erlangen, [2] Nuremberg (GERMANY)

10.50-11.00 APOCYNIN PREVENTS BLOOD PRESSURE RISING AND IMPROVES KIDNEY FUNCTION IN RATS WITH 5/6 NEPHRECTOMY
A. Vukovic, D. Karanovic, N. Mihailovic-Stanojevic, Z. Miloradovic, J. Nesovic-Sotojic, P. Brkic, M. Ivanov, S. Kovacevic, U.-J. Vajic, D. Jovovic, S.R. De Luka
Belgrade (SERBIA)

10.00-11.00 ROOM III

Oral Session 21

HYPERTENSION IN OLDER PERSONS

Chairperson: J. Polonia (Matosinhos, PORTUGAL)

10.00-10.10 EXPLORING THE BIDIRECTIONAL CAUSAL ASSOCIATION BETWEEN FRAILTY AND CARDIOVASCULAR DISEASES: INSIGHTS FROM A BIDIRECTIONAL MENDELIAN RANDOMIZATION STUDY
Z. Yin, H. Miao, S. Yang, Z. Zhou, Y. Zhang
Beijing (CHINA)

10.10-10.20 LARGE DIVERGENCES IN TARGET GROUPS OF ESH 2023 BP-LOWERING STRATEGIES IN OLDEST-OLD PATIENTS ACCORDING TO THEIR FUNCTIONAL AND/OR FRAILTY STATUS
K. Jagiello [1], K. Piotrowicz [2], T. Grodzicki [2], J. Gasowski [2], H. Kujawska-Danecka [1], T. Zdrojewski [1]
[1] Gdansk, [2] Krakow (POLAND)

10.20-10.30 ASSOCIATION OF BLOOD PRESSURE WITH MORTALITY IN OLDEST OLD PEOPLE WITH FRAILTY IN CHINA: RESULTS FROM CHINESE LONGITUDINAL HEALTHY LONGEVITY SURVEY (CLHLS)
L. Liu, H. Ruan, S. He, X. Chen
Chengdu (CHINA)

10.30-10.40 BLOOD PRESSURE EFFECTS OF TRAZODONE IN HYPERTENSIVE OLDER ADULTS
M. Capacci, G. Rivasi, L. Ceolin, G. Turrin, L. Rossi, S. Menale, M.F. Bisignano, A. Liccardo, E. Mossello, A. Ungar
Florence (ITALY)

10.40-10.50 ASSOCIATION BETWEEN ORTHOSTATIC HYPERTENSION AND FRAILTY AMONG OLDER PATIENTS WITH HYPERTENSION
K. Il Ki [1], J.-Y. Choi [1], D. Ryeol Ryu [2], H.-Y. Lee [3], M.-C. Cho [4], C.-H. Kim [1]
[1] Seongnam, [2] Chuncheon, [3] Seoul, [4] Cheongju (SOUTH KOREA)

10.50-11.00 Conclusion

10.00-11.00 **CONVENTION HALL I D**

Pathway: Cardiovascular Renal Protection

SEX SPECIFIC NEEDS IN CARDIOVASCULAR RENAL PROTECTION

Chairpersons: R. Cífková (Prague, CZECH REPUBLIC), C. Thomopoulos (Athens, GREECE)

10.00-10.15 **Primary hypertension: implications from the Hordaland health study**
E.A. Kringeland (Bergen, NORWAY)

10.15-10.20 **Discussion**

10.20-10.35 **Cardiovascular disease**
J. Brguljan (Ljubljana, SLOVENIA)

10.35-10.40 **Discussion**

10.40-10.55 **Chronic kidney disease**
K. Mayne (Glasgow, UNITED KINGDOM)

10.55-11.00 **Discussion**

10.00-11.00 **HALL EUROPE**

Pathway: Hypertension and Clinical Practice Guidelines

OPEN QUESTIONS FOR IMPLEMENTATION OF RENAL DENERVATION IN HYPERTENSION MANAGEMENT

Chairpersons: M. Azizi (Paris, FRANCE), F. Pinto (Lisbon, PORTUGAL)

10.00-10.15 **Technical aspects: which device?**
A. Schmid (Erlangen, GERMANY)

10.15-10.30 **How to assess adherence**
M. Burnier (Lausanne, SWITZERLAND)

10.30-10.45 **How to implement shared decision making**
J. Weil (Lübeck, GERMANY)

10.45-11.00 **Q&A**

11.15-12.30 **CONVENTION HALL II**

Plenary Session 3

HYPERTENSION AT CROSSROADS OF CARDIOVASCULAR RENAL PROTECTION - FUTURE CHALLENGES AND OPTIONS

Chairpersons: G. Grassi (Milan, ITALY), R. Kreutz (Berlin, GERMANY), R.E. Schmieder (Erlangen, GERMANY), T. Weber (Wels, AUSTRIA)

11.15-11.22 **Wearable cuffless devices for BP measurement**
G. Wuerzner (Lausanne, SWITZERLAND)

11.22-11.29 **AI in Hypertensive Heart Disease**
T. Kuznetsova (Leuven, BELGIUM)

11.29-11.36 **Evidence from Big Data**
G. Mancia (Milan, ITALY)

11.36-11.43 **siRNA knock-down of angiotensinogen- the future backbone of treatment**
A.J. Danser (Rotterdam, THE NETHERLANDS)

11.43-11.50 **Novel small molecules based therapies are still promising**
R. Kreutz (Berlin, GERMANY)

11.50-11.57 **Device-Based therapy beyond hypertension**
R.E. Schmieder (Erlangen, GERMANY)

11.57-12.04 **Precision medicine in hypertension**
C. Delles (Glasgow, UNITED KINGDOM)

12.04-12.30 **Final Plenary Discussion**
A.M. Heagerty (Manchester, UNITED KINGDOM)

13.30-15.00 **EXHIBITION AREA**

Moderated E-poster Session 3

TOTEM T01 Epidemiology
TOTEM T02 and T03 Blood Pressure Measurement
TOTEM T04 and T05 Heart, Brain, Vascculature
TOTEM T06 Risk factors
TOTEM T07 Clinical Studies
TOTEM T08 Secondary HTN and Diagnostic procedures
TOTEM T09 and T10 Children, Adolescents, Women
TOTEM T11 Diabetes, Obestiy, Comorbidities
TOTEM T12 Hypertension Phenotypes, Older Persons
TOTEM T13 and T14 Pharmacotherapy and Lifestyle interventions
TOTEM T15 and T16 General hypertension research

34th EUROPEAN MEETING ON HYPERTENSION AND CARDIOVASCULAR PROTECTION

MAY 23-26, 2025 - MILAN (ITALY)

NEW VENUE!

MICO NEW NORTH WING GATE 6
VIALE SCARAMPO - MILAN

European Society of Hypertension

eshannualmeetings.eu

MAKE YOUR CHOICE!

HELP SHAPE THE LOOK OF ESH 2025

Stop by the ESH 2025 booth at any time during the event and vote for your favorite graphic design!



ESH Gdańsk 2026

European Meeting on Hypertension and Cardiovascular Protection

May 29th – June 1st, 2026

Gdansk AmberExpo'

European Society of Hypertension